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ABSTRACT  
Elizabeth M. Garry: Study Design Choices for Evaluating Comparative Safety of Diabetic Medications  
(Under the direction of Til Stürmer) 
 
Background. Thiazolidinediones (TZDs) have been associated with an increased risk of heart 
failure (HF) and bladder cancer compared to dipeptidyl peptidase-4 inhibitors (DPP-4i’s). Safety 
estimates reported for bladder cancer vary widely due to heterogeneity of methods. The prevalent new 
user  design (PNU) has been proposed to overcome the power loss in active comparator, new user 
designs (ACNU) when new users of a drug have prior use of the comparison drug.  
Aims. (1.) Demonstrate the effect of varying study design choices to evaluate the safety of the 
TZD pioglitazone on bladder cancer; (2.) Evaluate the PNU to compare one-year HF incidence among 
DPP-4i versus TZD users, allowing DPP-4i users to switch from TZD.  
Methods. We identified Medicare beneficiaries aged >65 with diabetes and/or exposure to 
glucose-lowering drugs (GLDs) 2008-2015 and varied study design parameters on bladder cancer risk. 
For the PNU evaluating HF risk, TZD users were selected for each DPP-4i user matched on prior TZD 
duration and propensity to initiate or switch to DPP-4i. We used Cox proportional-hazards models to 
obtain hazard ratios (HR) and 95% confidence intervals.  
Results. Among the diabetic patients included in Aim 1, 135,188 had any exposure to 
pioglitazone and 1,375,024 did not. The HR for bladder cancer was 1.10[1.01-1.20] for pioglitazone users 
verses all nonusers when follow-up ignored treatment changes, and increased to 1.20[1.01-1.42] for the 
ACNU comparison to DPP-4i that accounted for treatment changes. In Aim 2, there were 59,058 DPP-4i 
new users and 2,929 who switched from TZD to DPP-4i. DPP-4i switchers were more likely than new 
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users to have comorbidities and diabetic complications. The HR for HF was 0.77 [0.71-0.83] for DPP-4i 
vs. TZD new users and 1.12 [0.77-1.63] for DPP-4i switchers vs. TZD continuers.  
Conclusions. Continued demand for new GLDs compels the need for more robust observational 
methods to evaluate safety and inform prescribing clinicians. The PNU showed little advantage over the 
ACNU with respect to sample size and highlights some pitfalls in the causal interpretation of PNU results. 
ACNUs that compare therapeutically equivalent drugs and account for treatment changes during follow-
up are recommended to minimize bias.  
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CHAPTER 1. SPECIFIC AIMS 
Diabetes affects at least one in five older adults (age ≥65) in the US and over 86% of older adults 
with diabetes require treatment with one or more glucose-lowering drugs (GLDs).1 The continued 
demand for new GLDs compels the need for robust observational methods to improve the value of real-
world evidence (RWE) and better understand their comparative effectiveness and safety. The safety of 
thiazolidinediones (TZD) has been debated for nearly twenty years despite being effective and generally 
well-tolerated.2 The Food and Drug Administration (FDA) added heart failure (HF) as a contraindication 
to the TZD label in 2002 and a safety warning was issued in 2007 that the TZD rosiglitazone may increase 
risk of myocardial infarction (MI).3 This was followed by a safety warning in 2011 that exposure more 
than two years to the TZD pioglitazone may increase the risk of bladder cancer,4 a warning that was later 
re-issued in December 2016.5 The dipeptidyl peptidase-4 inhibitors (DPP-4i) class of GLDs, was 
introduced in 2006 at the start of a decline in TZD use triggered by the publicity surrounding the safety 
warnings.  
Several studies have reported on the safety of pioglitazone; many including a 10-year safety 
study requested by the FDA6 reported no evidence to suggest an increased risk of bladder cancer 
associated with pioglitazone use,6-14 while others reported an increased risk.15-19 It is difficult to 
determine safety when the totality of evidence from the trials and observational studies vary widely. 
Most of the variation can be attributed to differing methodological design choices, such as inclusion or 
exclusion of prevalent users, choice of referent group, and the definition of the follow-up period used 
for case ascertainment. An active comparator, new user design (ACNU) that compared DPP-4i’s to TZD 
reported a decreased 1-year risk of HF (RR, 0.71 [95% CI: 0.53-0.93].20 The ACNU has been criticized 
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because additionally excluding prevalent users might lead to smaller sample size if many new users of 
one of the drug classes compared have been treated with the other drug class previously. The prevalent 
new user design (PNU) has been proposed to include all or most patients exposed to the newer drug, as 
it allows for those who switch from the older drug to the newer drug to be included.21  
The specific aims of this project are:  
Specific Aim 1: Demonstrate how study design affects relative bladder cancer incidence 
among pioglitazone users by varying new versus existing drug use, the choice of the referent group (all 
nonusers of pioglitazone; users of all GLDs other than pioglitazone; users of all non-insulin GLDs 
(NIGLDs) other than pioglitazone; and users of DPP-4i’s), and whether or not follow-up is censored 
according to treatment change using Medicare claims data 2007-2015. 
Hypothesis: We hypothesized that prevalent user cohorts that compared pioglitazone to a 
composite referent group of all nonusers of pioglitazone (the least meaningful treatment alternative) 
would yield estimates closest to null, and that comparative estimates would get further from the null 
showing an increase in risk associated with pioglitazone as the referent group became more meaningful 
from all nonusers to GLD, NIGLD, and DPP-4i, respectively.     
Rationale: The 10-year safety study that compared pioglitazone users to all diabetic patients 
who were nonusers of pioglitazone reported no increased risk of bladder cancer. An ACNU that used 
Medicare data to compare new users of pioglitazone to new users of DPP-4i reported an increased risk 
of bladder cancer.  
Specific Aim 2: Evaluate the use of the proposed PNU within Medicare claims data 2007-2015 
to compare one-year HF hospitalization rates among users of DPP-4i, a newer GLD, to users of TZD, an 
older GLD, allowing for DPP-4i users to switch from TZD. 
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Hypothesis: We hypothesized that patients who switched from TZD to DPP-4i would have higher 
risk of HF than traditional new users without prior TZD and patients who continue on TZD without 
switching to DPP-4i, respectively.    
Rationale: It is likely that the reason patients switch from TZD to DPP-4i is due to failure to 
achieve or maintain target blood glucose levels and/or are contra-indicated for continuation of TZD 
therapy, which would increase the risk for HF. Patients who continue TZD without switching are likely 
able to maintain target blood glucose, which would put them at lower risk of HF.  
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CHAPTER 2. BACKGROUND AND REVIEW OF LITERATURE 
2.1. Background and Significance 
Diabetes mellitus is a growing public health concern that affects more than 25% of older adults 
(those aged 65 or older).22 Type-2 diabetes mellitus (T2DM) accounts for 90-95% of all diabetes cases 
diagnosed in adults.23 The annual cost of diabetic care in the United States (US) is estimated at $245 
billion; diabetic care for older adults, most of which is paid for by Medicare, accounts for approximately 
59% of these annual costs.24 Patients with diabetes lack the ability to process carbohydrates. Although 
some are able to achieve and maintain target blood glucose levels via diet and exercise, most patients 
will require a glucose-lowering drug (GLD). Metformin is the preferred initial therapy recommended by 
the American Diabetes Association at the time of T2DM diagnosis, but additional GLDs are added 
commonly added when maximum tolerated dose does not achieve and maintain target blood glucose 
levels. The increasing prevalence of diabetes and adverse effects and inadequate efficacy of currently 
available GLDs has supported a continued demand for new GLDs to enter the market and subsequently 
a continued demand for more robust observational methods to evaluate their safety. 
 
2.2. Review of the Literature 
2.2.1. Literature on the safety of TZDs and bladder cancer and cardiovascular risks  
The safety of the thiazolidinedione (TZD) class of GLDs has been a topic of debate for nearly 
twenty years.  Despite the removal of the first TZD, troglitazone, shortly after its 1997 approval due to 
hepatotoxicity,25 the two remaining TZDs, rosiglitazone and pioglitazone, gained quick popularity 
following their 1999 approval as highly effective at achieving and maintaining target blood glucose 
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levels2,26-34 and generally well-tolerated as monotherapy33-35 or in combination with other oral GLDs.35,36 
TZDs reduce blood glucose levels by binding to and activating peroxisome proliferator-activated 
receptor gamma (PPARγ) in insulin-sensitive tissues (i.e. skeletal muscle, liver, and adipose tissue), 
thereby decreasing insulin resistance.37,38 It has been suggested that insulin resistance may act as a 
predictor of cardiovascular (CV) risk among patients with T2DM independent of its effect on the body’s 
ability to process sugar.39 Preclinical studies of TZDs identified a reduced risk of MI and improved 
contractile function among rats with cardiac ischemia and reperfusion injury, most likely due to 
inhibition of the inflammatory response.40 However, in 2002, the Food and Drug Administration (FDA) 
added heart failure (HF) to the TZD package insert as a contraindication along with a safety warning that 
TZDs may cause or exacerbate HF. In 2007, the FDA issued a safety warning that rosiglitazone may 
increase the risk of MI.3 This was followed by a warning in 2011 that pioglitazone exposure more than 
two years may increase the risk of bladder cancer,4 a warning that was later re-issued in 2016.5 
Two large placebo-controlled randomized controlled trials (RCTs) evaluated the CV safety of 
pioglitazone, the PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events)34 and the 
IRIS (Insulin Resistance Intervention after Stroke) trials,15 which included over 5000 T2DM patients with 
established CV disease and nearly 4000 non-diabetic patients with insulin resistance who had a recent 
ischemic stroke or transient ischemic attack, respectively. No evidence of an increased risk of non-fatal 
MI and stroke was suggested by results from the three-year PROactive trial (hazard ratio, HR, 0.83 [95% 
CI: 0.65-1.06] and 0.81 [95% CI: 0.61-1.07], respectively),34 a follow-up study that observed 74% of the 
PROactive patients for an additional mean of 7.8 years (HR, 1.07 [95% CI: 0.88-1.30] and 1.09 [95% CI: 
0.90–1.31]),14 or during a median follow-up of 4.8 years in the IRIS trial that evaluated the composite 
endpoint of MI or stroke (HR, 0.76 [95% CI: 0.62-0.93]).15 Furthermore, no evidence of an increased risk 
of a composite CV endpoint was suggested by results from the PROactive trial or its observational 
follow-up study (HR, 0.90 [95% CI: 0.80-1.02] and 0.74 [95% CI: 0.55-0.99], respectively).14,34 
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 The CV safety warnings for TZDs were in response to a meta-analysis that reported an increased 
risk of MI and CV mortality (OR, 1.43 [95% CI: 1.03-1.98] and 1.64 [95% CI: 0.98-2.74], respectively).36 
After receiving criticism for not including all trials,41-43 the authors published a revised meta-analysis that 
also included 14 trials with null values for CV events in addition to the original 42 trials requiring follow-
up greater than 24 weeks, which yielded attenuated pooled estimates for MI and CV mortality (OR, 1.28 
[95% CI: 1.01-1.62] and 0.99 [95% CI: 0.75-1.32], respectively).44 A subsequent meta-analysis requiring a 
minimum of 4 weeks of follow-up that included 164 trials reported no evidence suggesting an increased 
risk of nonfatal MI, all-cause mortality, and CV mortality (OR, 1.14 [95% CI: 0.90-1.45], 0.93 [95% CI: 
0.76-1.14], and 0.94 [95% CI: 0.68-1.29], respectively), but did report evidence suggesting increased risk 
of HF (OR, 1.69 [95% CI: 1.21-2.36]), which was more pronounced when rosiglitazone was used 
concurrently with insulin (OR, 2.20 [95% CI: 1.28-3.78]). A nested case-control studies that matched 
twenty controls per case to compare TZD users to nonusers among elderly diabetic patients reported an 
increased risk of MI and HF hospitalizations (HR, 1.41 [95% CI: 1.21-1.65] and 1.94 [95% CI: 1.71-2.19], 
respectively), and no evidence of increased risk of CV mortality, all-cause mortality, and stroke 
hospitalization (HR, 0.88 [95% CI: 0.69-1.12], 0.87 [95% CI: 0.76-0.99], and 1.14 [95% CI: 0.97-1.34], 
respectively).45 The Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in 
Diabetes (RECORD) trial confirmed an increased risk of HF reporting increased HF hospitalization for 
rosiglitazone in combination with sulfonylureas compared to rosiglitazone in combination with 
metformin (HR, 2.10 [95% CI: 1.35-3.27]), but no increased risk of MI (HR, 1.14 [95% CI: 0.80-1.63).46 
Although PPARγ expression is most prominent in fat, it is also expressed at some level in other 
cell types. TZDs have been shown to decrease bladder cancer cell growth in other carcinomas such as 
the pancreas, colon, liver, and prostate by inducing apoptosis via PPARγ activation.47 Preclinical studies 
of pioglitazone reported excess bladder tumors in rats.48 This was thought to be a rat-specific 
phenomenon49 until the PROactive trial reported excess bladder tumors in humans assigned 
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pioglitazone compared to placebo (0.5%[N=14] vs. 0.2%[N=6]) in 2005,34 which resulted in the FDA to 
request a 10-year safety study. The safety warning issued for pioglitazone in 20114 was in response to 
interim results of the 10-year study that reported an increased risk of bladder cancer after two-year 
exposure to pioglitazone compared to nonuse of pioglitazone (HR, 1.44 [95% CI: 1.03–2.02]).6 Multiple 
publications followed that reported no evidence to suggest an increased risk of bladder cancer 
associated with pioglitazone use,6-14 including the final results from the 10-year study (HR, 1.06 [95% CI: 
0.89-1.26])6 and the PROactive observational follow-up study (RR, 1.05 [95% CI: 0.61–1.79].14 Far fewer 
publications reported an increased risk overall.15-19 These include comparisons of pioglitazone users to 
nonusers of TZD at the time of pioglitazone initiation (HR, 1.63 [95% CI: 1.22-2.19]),18 never users of 
pioglitazone (RR,1.83 [95% CI: 1.10- 3.05]),16 placebo (0.6%[n=12] vs. 0.4%[n=8]) in the IRIS trial,15 and to 
new users of dipeptidyl peptidase-4 inhibitors (DPP-4i’s) (HR,1.57 [95% CI: 1.23-2.00]) and sulfonylureas 
(HR,1.32 [95% CI: 1.02-1.70]) among a national sample of older US adults in our recent.19 It is unclear 
whether pioglitazone creates a setting for development or progression of bladder malignancy. 
 
2.2.2. Literature on the safety of DPP-4i’s and CV risks  
DPP-4i’s are incretin-based agents that improve glycemic control by increasing insulin secretion 
and suppressing glucagon levels.50 The first of the DPP-4i’s, sitagliptin, was approved in 2006 and was 
followed by saxagliptin in 2009, linagliptin in 2012, and alogliptin in 2013. DPP-4i’s, like TZDs, effectively 
increase glycemic control without causing hypoglycemia, but unlike TZDs, are not associated with weight 
gain.2 Patients with diabetes have an increased risk of developing CV disease,51,52 namely MI, HF, and 
stroke.52 Therefore, following the controversy surrounding the CV risk associated with TZD use, the FDA 
Endocrinologic and Metabolic Drugs Advisory Committee proposed a requirement for sufficient 
exposure in patients at high risk for CV events to exclude an unacceptable risk for CV events (upper limit 
of the 95% CI <1.8 for marketing authorization and <1.3 in post-approval trials.53 Therefore, a number of 
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trials were conducted to evaluate the long-term safety and efficacy of DPP-4i’s, including EXAMINE 
(Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care), SAVOR-TIMI53 
(Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-
Thrombolysis in Myocardial Infarction), and TECOS (The Trial to Evaluate Cardiovascular Outcomes after 
Treatment with Sitagliptin). Each of these trials demonstrated point estimates for the primary composite 
CV endpoint indicating a lack of effect of DPP-4i’s on CV events.  
Multiple meta-analyses of DPP-4i trials have also been conducted to pool estimates from DPP-4i 
trials. One included only the three key placebo-controlled trials (EXAMINE, SAVOR-TIMI53, TECOS) as it 
required at least 1000 patients in each trial,54 another included all registered placebo-controlled trials,55 
and two included active comparator trials in addition to placebo-controlled.56,57 Among the pooled 
estimates, there was no evidence to suggest increased risk of all-cause mortality, CV mortality, MI, 
stroke, or major adverse coronary events (MACE).54-57 When active comparator trials were included, 
pooled estimates yielded evidence of a decreased risk associated with DPP-4i use compared to other 
GLDs for MACE, MI, stroke, and all-cause mortality (ORMH, 0.71 [95% CI: 0.59-0.86], 0.64 [95% CI: 0.44-
0.94], 0.77 [95% CI: 0.48-1.24], and 0.60 [95% CI: 0.41-0.88], respectively),56 as well as any CV event and 
nonfatal MI or acute coronary syndrome (RR, 0.48 [95% CI: 0.31-0.75] and 0.40 [95% CI: 0.18-0.88], 
respectively),57 suggesting a CV benefit of DPP-4i’s. Contrary to multiple other CV-related outcomes, 
pooled estimates suggested that DPP-4i’s are associated with an increased risk of HF (RR, 1.11 [95% CI: 
0.95-1.30], 1.13 [95% CI: 1.01–1.26], and ORMH, 1.19 [95% CI: 1.03-1.37]).54,55,58 Many of the pooled 
estimates were similar to individual estimates of the three large trials individually given the large sample 
sizes of each trial. However, only the SAVOR-TIMI53 trial reported more hospitalizations for HF among 
patients treated with DPP-4i than placebo group (3.5 vs. 2.8%; HR, 1.27 [95% CI: 1.07-1.51]).59 In 
response, the FDA requested the clinical trial data from manufacturers of saxagliptin to explore this 
further.60 Two years later, in 2016, the FDA issued a warning that the two DPP-4i’s saxagliptin and 
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alogliptin may increase the risk of HF.5 
Observational studies examining CV risk report no increased risk of MI and stroke associated 
with DPP-4i use, but the evidence on HF is mixed.20,61-72 Among the studies comparing DPP-4i’s to a 
combination of other GLDs, two reported a reduced rate of HF64,69 while two others reported an 
increased rate of HF.70,71 There was much variation among the four studies that suggested no difference 
in effect for HF.20,62,68,72 Of which, one used a case-control design to compare current incretin use to non-
use,72 one compared two DPP-4i’s head-to-head, saxagliptin versus sitagliptin,62 one compared DPP-4i 
users to matched nonusers,68 and one compared initiators of DPP-4i to initiators of sulfonylureas and 
then initiators of TZDs.20 
 
2.2.3. Design choices for evaluating comparative safety of diabetic medications 
Much has been published on the potential risks of TZD use to date, but it is difficult to 
determine safety when the totality of evidence reports differing estimates. Similar differences have now 
been reported for the association between DPP-4i’s and HF, because the issues related to study design 
considerations remain. Explanations include referent choice, differing data sources and study types, 
whether or not prevalent users are included, and how the risk window is defined. An incident user 
design with a referent that is a clinically meaningful treatment alternative is recommended for 
comparative effectiveness research to present the least biased comparison.73-75  
Confounding by severity threatens study validity when there are major differences in disease 
severity between those prescribed the exposure and the referent.73,74 Referent choice can therefore 
strongly influence both the interpretation and generalizability of comparative estimates. When 
evaluating the safety of a specific diabetic drug or class of drugs, some may consider including all 
diabetic patients who are nonusers of the drug(s) of interest as the referent for comparison. This was 
observed in literature evaluating the associations between pioglitazone and bladder cancer7,10,11,13,16-
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18,76,77 and DPP-4i’s and HF.68-71 Mixing therapies prescribed to patients with varying degrees of diabetes 
severity makes it difficult to disentangle individual treatment effects and increases the potential for 
biased estimates. Including untreated patients with diabetes in the referent group6,11 can threaten 
validity further due to confounding by indication, since these patients may be able to manage their 
diabetes without medical therapy (e.g., diet and exercise). Alternatively, such patients may be non-
compliant to prescribed medications, which may increase the severity of their disease.  
TZDs and DPP-4i’s are both classes of drugs prescribed to similar patients,19,78 making them 
examples of clinically meaningful treatment alternatives with therapeutic equipoise. Channeling is a 
form of allocation bias, where drugs with similar therapeutic indications are prescribed to groups of 
patients with prognostic differences.79 When new drugs or classes of drugs enter the market, they may 
be channeled to specific types of patients, such as those newly diagnosed with a disease or those who 
failed treatment on alternative drugs. Conversely, drug safety concerns, especially FDA warnings, may 
lead to preferential prescribing of the drug to patients with the lowest risk of the safety outcome. 
Therefore, the calendar time when a drug is prescribed may influence its probability of being prescribed. 
80,81 The first DPP-4i was introduced to the market at the peak of TZD sales when the initial safety 
warning for TZDs was issued. Between 2006 and 2013, distribution of the market-share among privately 
insured T2DM patients increased from 0.5% to 14.9% for DPP-4i’s, while simultaneously decreasing from 
28.5% to 5.6% for TZDs.77 This pattern suggests that prescribers who would have previously prescribed a 
TZD to certain patients before the warnings would likely prescribe a DPP-4i to such patients afterwards. 
Therefore, calendar time is a likely instrumental variable that can be used to assign treatment.78,81  
The ACNU excludes existing users, which provides some assurance that baseline covariates are 
measured prior to treatment initiation and that follow-up assessment occurs after exposure is initiated, 
providing the temporality necessary to make causal inferences treatment safety.82 Covariates measured 
after treatment initiation among existing users may already be influenced by the treatment. Adjusting 
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for variables that occur in the causal pathway between treatment and outcome can generally bias 
estimation of treatment effects toward the null.83,84 The ACNU minimizes these biases.85-87 The trade-off 
however is that restricting to completely treatment-naïve subjects also restricts sample size.88 When 
comparing newer therapies like DPP-4i’s to older alternatives like TZDs via new user design, many new 
therapy patients may be excluded due to prior exposure to the older therapy. Therefore, an argument 
has been made for a hybrid approach that allows for inclusion of all or most patients exposed to the 
newer drug and compares them to a combination of new and existing users of the older drug utilizing a 
prevalent new user comparative cohort design.21  
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CHAPTER 3. METHODS 
3.1. Study Designs, Exposure, and Comparisons 
For Aim 1, we systematically compared different study designs, varying new versus existing drug 
use, choice of the referent group, and whether follow-up was censored according to treatment change 
(“as-treated” [AT] censoring approach) or not (“initial treatment” [IT] censoring approach). The referent 
choice started with all nonusers of pioglitazone (treated and untreated) as was done in the 10-years 
safety study requested by the FDA,6 and then we restricted to a composite of all nonusers of 
pioglitazone who were treated, first including all patients with any GLD other than pioglitazone and then 
further restricting to all patients with a non-insulin GLD (NIGLD) other than pioglitazone, as insulin use is 
associated with more severe diabetes. The last referent choice was DPP-4i, as thought to be the optimal 
comparator for pioglitazone initiators since prescribed to similar patients.19,78 ACNUs that compare the 
initiation of the drug of interest to the initiation of a clinically meaningful treatment alternative have 
been recommended for comparative effectiveness research to present the least biased 
comparison.73,74,85,87 The AT censoring approach minimizes potential for exposure misclassification while 
still providing the option to extend follow-up after end of exposure to allow for disease manifestation 
and diagnosis for cancer outcomes (latency period).89  
For Aim 2, we explored the use of the prevalent new user design (PNU) to compare DPP-4i to 
TZD, allowing for DPP-4i to have prior TZD. This design has been proposed to additionally include the 
exposed patients who have been treated with the referent drug class previously, who would otherwise 
be excluded from traditional ACNUs. To do so, we first created exposure sets for each DPP-4i user that 
included all TZD users for each new DPP-4i user or a subset of TZD continuers with the same TZD 
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duration (± 30 days) for each DPP-4i switcher. The TZD user with the closest propensity to initiate or 
switch to DPP-4i among all exposure sets conditional on time-varying covariates was selected to form 
1:1 matched pairs within the cohort.  
 
3.2. Data Source 
For both Aims 1 and 2, data was abstracted from a 20% random sample of Medicare Parts A 
(inpatient), B (outpatient) and D (prescription) adjudicated claims data from January 1, 2007 (start of 
available data) to December 31, 2015 (end of available data). Medicare provides public insurance to 
over 98% of older US adults, and contains information about demographic and enrollment 
characteristics, diagnoses, procedures, and dispensed prescriptions for enrollees.90  
Within Medicare Parts A and B, all diagnoses for medical conditions are recorded via 
International Classification of Diseases, Ninth Revision (ICD-9) on or prior to September 30, 2015 and via 
International Classification of Diseases, tenth Revision (ICD-10) codes after. All inpatient or outpatient 
procedures are recorded via Current Procedural Terminology, Fourth edition (CPT-4) or Healthcare 
Common Procedure Coding System (HCPCS) codes. Within Medicare Part D, claims for prescriptions 
dispensed are recorded via National Drug Codes (NDC) codes. 
 
3.3. Study Populations 
For Aim 1, in attempt to mimic a diabetic registry as was used in the 10-year safety study 
requested by the FDA,6 we included all patients with diabetes (ICD-9-CM: 250.x; 2 outpatient claims 
within 365 days or 1 inpatient claim) with at least 365 days of continuous enrollment prior to the first 
inpatient or second outpatient claim during the study period. GLD exposure was then classified as 
pioglitazone, rosiglitazone, DPP-4i’s, metformin, sodium-glucose co-transporter-2 inhibitors (SGLT-2), 
sulfonylureas, long-acting insulin, short-acting insulin, or other GLD (alpha-glucosidase inhibitors, amylin 
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analogs, glucagon-like peptide-1s, and meglitinides; Appendix 1). New use of GLD exposure was 
determined based on no prescription claims for the drug classes included in each comparison during the 
365-day period prior to the initial claim. Each patient was then hierarchically classified as exposed to 
pioglitazone (≥2 prescription claims for any pioglitazone within 180 days), GLD (≥2 prescription claims 
for the same non-pioglitazone GLD class within 180 days), single GLD (≥1 prescription claim for a GLD 
but not ≥2 prescription claims for the same GLD class within 180 days), or untreated (no prescription 
claims for a GLD). Patients aged less than 66 upon cohort entry or with a diagnosis of prevalent bladder 
cancer or common bladder cancer treatment procedures (bacillus Calmette-Guérin immunotherapy, 
bladder instillation of a chemotherapeutic agent, cystectomy, implementation of chemotherapeutic 
agent, other genitourinary instillation, injection or infusion of cancer chemotherapeutic substance; 
Appendix 2) at any time prior were excluded prior to forming the varied comparison groups described 
above.  
For Aim 2, we started with a base cohort of all users of DPP-4i (largely sitagliptin and saxagliptin) 
and thiazolidinediones (largely pioglitazone) between January 1, 2007 and September 30, 2015 who had 
no prior prescription fills for their own drug class within the 180 days prior. Patients who received both 
were considered for inclusion in both the exposed and the referent groups, but patients were excluded 
if they had a fill for both TZD and DPP-4i on the same day. Patients who received DPP-4i within the 180 
days prior to TZD were considered as DPP-4i users only censoring follow-up upon TZD initiation. Only the 
first eligible use period of either DPP-4i or TZD was included. To minimize potential for selection bias, 
the following exclusions were applied to each exposure set at the time of matching within each 
sequential exposure set: less than 365 days of continuous enrollment prior to the index date, age less 
than 66 on the index date, or any inpatient or outpatient HF or loop diuretic at any time prior to the 
index date using all available data.  
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3.4. Outcomes 
For Aim 1, incident bladder cancer events were defined by the presence of at least two 
diagnostic claims for bladder cancer between 1 and 60 days apart, an algorithm previously validated for 
other solid tumors in Medicare data.91 We included carcinoma in situ of the bladder (ICD-9: 233.7; ICD-
10: D09.0) in addition to all other bladder cancer (ICD-9: 188.x; ICD-10: C67.x, C79.11) diagnosis codes 
since the majority of bladder cancers are diagnosed at an early stage.6,92 The first claim date defined the 
event date, as thought to be closest to date of actual diagnosis.  
Prevalent bladder cancer for the purpose of exclusions additionally included diagnosis of 
personal history of bladder cancer (ICD-9: V10.5, V10.50, V10.51) or common bladder cancer treatment 
procedures (bacillus Calmette-Guérin immunotherapy [CPT-4: 90586], Bladder instillation of a 
chemotherapeutic agent [CPT-4: 51720], cystectomy [CPT-4: 51570, 51575, 51580, 51585, 51590, 
51595, 51596, 51597], implementation of chemotherapeutic agent [ICD-9: 00.10], Other genitourinary 
instillation [ICD-9: 96.49], injection or infusion of cancer chemotherapeutic substance [ICD-9: 99.25]). 
Although radiation and transurethral resection of bladder tumor (TURBT), and partial cystectomy 
procedures may be used to treat bladder cancer, prevalent bladder cancer will not be defined using 
these procedures without the additional occurrence of a bladder cancer claim. This is because radiation 
may be used for treatment for cancer sites other than bladder, TURBT procedure may be either 
diagnostic or therapeutic, and a partial cystectomy may be performed for management of benign 
conditions of the bladder such as bladder diverticula. 
For Aim 2, hospitalization for HF, defined as inpatient diagnosis in any position of HF, rheumatic 
HF, malignant, benign, or unspecified hypertension with HF, hypertensive heart and kidney disease with 
HF that is malignant, benign, or unspecified and stage I-IV or V/end-stage (ICD-9: 428.x, 398.91, 402.01, 
402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 404.13, 404.93). Hospitalization for HF using 428.x in the 
primary position was considered given near perfect specificity (>98%), but expanded upon due to very 
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low sensitivity of 21% reported in a Medicare population. 93 
 
3.5. Follow-up 
For Aim 1, the cohort entry was defined as the date of the second prescription fill for those with 
at least 2 prescription claims within 180 days (pioglitazone and GLD categories), the first prescription fill 
for those with at least 1 prescription fill who did not have at least 2 prescription claims within 180 days 
(single GLD), and the date of the qualifying diabetes claim for those untreated. For Aim 2, ACNU 
matches were assigned an index date based on the first prescription claim. The patients who switched 
from TZD to DPP-4i were assigned an index date based on the first DPP-4i prescription claim, while TZD 
continuers were assigned an index date based on the subsequent TZD prescription refill date that 
occurred on the day when TZD duration was equal to the prior TZD duration of the corresponding DPP-4i 
switcher (± 30 days).  
The primary follow-up period used for both aims to identifying events (bladder cancer and HF, 
respectively) was an “as-treated” (AT) approach, which continued until first occurrence of death, 
disenrollment, study end, or treatment discontinuation (no subsequent dispensing for initiated drug 
class within days-supply plus a 90-day grace period). We additionally included an “initial-treatment” (IT) 
approach that did not censor on treatment discontinuation, similar to the intent-to-treat approach used 
in RCTs. 
For the bladder cancer outcome of Aim 1, the follow-up period for the AT analyses was lagged to 
begin 180 days after the cohort entry date to allow for time between exposure and development of 
disease (induction period) to exclude cases immediately following exposure to reduce the potential for 
spurious associations attributable to increased medicalization after start of a therapy or the possibility of 
preclinical symptoms of bladder cancer influencing treatment choice (protopathic bias). Patients who 
died or had the outcome within the first 180 days of follow-up were excluded from the analytic cohort. 
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Given that pioglitazone was on the market longer than some of the newer drugs, such as DPP-4i’s and 
SGLT-2i’s, follow-up was truncated at 5 years. We analyzed overall follow-up and follow-up stratified at 
two years, based on the original FDA safety warning. Only the subset of patients not otherwise censored 
within two years were included in analyses evaluating associations two years after cohort entry.  
 
3.6. Statistical Analyses 
Crude incidence rates of bladder cancer (Aim 1) and HF (Aim 2) were calculated based on the 
Poisson distribution overall and for each treatment category (first event per patient). Cox proportional 
hazards models were used to estimate the Hazard Ratios (HR) and 95% Confidence Intervals (CI) for 
incident events. Crude models included treatment as the only independent variable.  
For Aim 1, partially adjusted models included treatment, age, sex, race, and age-squared as 
independent variables. To be consistent with the 10-year safety study requested by the FDA,6 
multivariable outcome regression models were used to obtain fully adjusted HRs. We also added a 
multivariate model to adjust for year of index date to account for calendar-time trends, using 2011 as 
the referent year. Differences in the confounder distributions were inspected for successful confounder 
balance of measured characteristics. Exposure-specific PS distributions were plotted to inspect the 
suitability of the matched referent groups.94 (See Figure S1) All data were analyzed in SAS, v9.4.  
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CHAPTER 4. MANUSCRIPT 1: DEMONSTRATE HOW STUDY DESIGN AFFECTS RELATIVE BLADDER 
CANCER INCIDENCE AMONG PIOGLITAZONE USERS BY VARYING NEW VERSUS EXISTINGDRUG USE, 
THE CHOICE OF REFERENT GROUP, AND WHETHER OR NOT FOLLOW-UP IS CENSORED ACCORDING TO 
TREATMENT CHANGE USING MEDICARE CLAIMS DATA 2007-2015. 
 
4.1. Introduction 
Diabetes affects at least one in five older adults (age ≥65) in the US and over 86% of older adults 
with diabetes will require treatment with one or more glucose-lowering drug (GLD).1 The continued 
demand for new GLDs compels the need for robust observational methods to improve the value of real-
world evidence (RWE) and better understand their comparative effectiveness and safety. The safety of 
the pioglitazone, a GLD from the thiazolidinedione (TZD) class, has been debated for nearly twenty years 
despite being generally well-tolerated.2 The Food and Drug Administration (FDA) issued a safety warning 
that TZDs may increase and/or exacerbate heart failure (HF) in 2007.3 This was followed by a safety 
warning in 2011 that exposure more than two years to pioglitazone may increase the risk of bladder 
cancer,4 a warning that was later re-issued in December 2016.5  
Several studies have reported on the safety of pioglitazone (Table 4.1); many reported no 
evidence to suggest an increased risk of bladder cancer associated with pioglitazone use,6-14 while others 
reported an increased risk.15-19 The safety estimates of these studies varied widely. This is likely driven by 
the different study design choices, which obscures the association between pioglitazone and bladder 
cancer and makes it difficult to determine the actual safety. The majority of observational studies 
evaluating this association included all users of pioglitazone without requiring new use;6-8,11,12,17,76,95-100 
most of which did not report evidence of an increased risk of bladder cancer. Very few studies compared 
pioglitazone to a single drug (or class of drugs).9,19,101 Many studies identified all diabetic patients and 
then compared patients treated with pioglitazone to one composite referent group of all non-
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pioglitazone. While some restricted the composite referent group to patients treated with a GLD7,11,17,76 
or a non-insulin GLD (NIGLD)10,16,18 other than pioglitazone, many included both those treated and 
untreated with a GLD.6,8,12,95-97,99,100 Among the comparisons with referent groups that additionally 
included untreated patients, reports of no evidence to suggest an increased risk of bladder cancer was 
common, whereas estimates from comparisons to treated GLD or NIGLD referent groups had more 
variation. Few studies accounted for exposure duration,6,11,17-19,95,100 and only two studies that we 
reviewed censored follow-up based on exposure change in addition to outcome, death, or end of 
study.17,19 Few studies lagged the exposure period to allow for a sufficient time to allow for development 
and detection of malignancy (i.e. latency period), excluding outcomes that occur immediately after start 
of treatment.16-19 Studies that accounted for exposure changes or lag/latency tended to identify effect 
estimates furthest from the null, commonly reporting an increased risk of bladder cancer.  
Using the example of pioglitazone and bladder cancer among older adults, we sought to 
understand the impact of heterogeneity of study design on studies evaluating safety of diabetic 
medications. This paper aims to demonstrate the importance of how exposure is defined, what 
exposure is being compared to, and when to identify safety endpoints. We varied new versus existing 
drug use, the choice of the referent group (all non-pioglitazone patients; users of all GLDs other than 
pioglitazone; users of all NIGLDs other than pioglitazone; and users of dipeptidyl peptidase-4 inhibitors 
[DPP-4i]), and whether or not follow-up is censored according to treatment change.  
 
4.2. Methods 
4.2.1. Study Population 
In the 10-year safety study requested by the FDA, patients were selected from a diabetic registry 
and exposure was assigned hierarchically classifying according to the first group that they qualify for 
during the cohort entry period without regard to treatment change.6 Before creating our varied referent 
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groups, we first attempted to mimic this design. Therefore, we first selected a cohort of patients with a 
diagnosis of diabetes as our study population. Diabetes was defined as 2 outpatient claims within 365 
days or 1 inpatient claim (ICD-9-CM: 250.x), with at least 365 days of continuous enrollment prior to the 
first inpatient or second outpatient claim during the study period.  
 
4.2.2. Exposure 
We identified GLD exposure based on a prescription claim for any GLD with an NDC that 
corresponds to an anatomical therapeutic chemical (ATC) classification system code starting with A10102 
and classified exposure as pioglitazone, rosiglitazone, DPP-4i’s, metformin, sodium-glucose co-
transporter-2 inhibitors (SGLT-2i’s), sulfonylureas, long-acting insulin, short-acting insulin, or other GLD 
(alpha-glucosidase inhibitors, amylin analogs, glucagon-like peptide-1s, and meglitinides; Appendix 1). 
Patients who had combination therapy were classified according to all drug classes they were exposed 
to. For example, a patient who received sitagliptin/metformin combination was classified as both DPP-4i 
and metformin.  New use of GLD exposure was determined based on no prescription claims for the drug 
classes included in each comparison during the 365-day period prior to the initial claim. Each patient 
was then hierarchically assigned to one of four mutually exclusive exposure categories based on the 
presence or absence of pharmaceutical claims between January 2008 and September 2015 prior to 
death or disenrollment: 
1. Pioglitazone: Patients with ≥2 prescription claims for any pioglitazone within 180 days; or  
2. GLD: Patients with ≥2 prescription claims for the same GLD class within 180 days who did 
not otherwise qualifying for Category 1, including rosiglitazone; or  
3. Single GLD: Patients with ≥1 prescription claim for a GLD who did not otherwise qualifying 
for Categories 1 or 2, including patients with only 1 pioglitazone claim; or 
4. Untreated: Patients with no prescription claims for a GLD. 
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Cohort entry was defined as the date of the second prescription fill for Categories 1-2, the first 
prescription fill for Category 3, and the date of the qualifying diabetes claim for Category 4 (Figure S2). 
The earliest possible cohort entry date was January 1, 2008 after requiring at least 365 days of 
continuous enrollment and the latest possible cohort entry date was July 2, 2015 to allow all patients to 
have at least 180 days of follow-up. Patients aged less than 66 upon cohort entry or with a diagnosis of 
prevalent bladder cancer or common bladder cancer treatment procedures (bacillus Calmette-Guérin 
[BCG] immunotherapy, bladder instillation of a chemotherapeutic agent, cystectomy, implementation of 
chemotherapeutic agent, other genitourinary instillation, injection or infusion of cancer 
chemotherapeutic substance; Appendix 2) at any time prior were excluded. 
 We then created our four varied referent groups that we used to compare pioglitazone users to 
(Table S3). The first composite referent group consisted of all non-pioglitazone patients from Categories 
2-4, as was done in many of the previous studies.6,7,10,11,13,16-18,76,77 The second was a GLD referent group 
from Category 2. The third was a non-insulin GLD (NIGLD) referent group from Category 2 except insulin 
users.  The fourth was restricted to DPP-4i users from Category 2. We also explored some of the 
components of the non-pioglitazone composite referent group, metformin, long-acting insulin, and 
untreated, as individual referent groups, as these were thought to be most influential (Figure 4.1). The 
all-user cohorts included all patients according to first qualifying referent group, and the new user 
cohorts included patients classified according to first new user referent group that they qualify for 
during the cohort entry period. 
 
4.2.3. Outcome 
Incident bladder cancer events were defined by the presence of at least two diagnostic claims 
for bladder cancer between 1 and 60 days apart, an algorithm previously validated for other solid 
tumors in Medicare data.91 We included carcinoma in situ of the bladder (ICD-9: 233.7; ICD-10: D09.0) in 
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addition to all other bladder cancer (ICD-9: 188.x; ICD-10: C67.x, C79.11) diagnosis codes since the 
majority of bladder cancers are diagnosed at an early stage.92 (Appendix 2) The first claim date defined 
the event date, as thought to be closest to date of actual diagnosis.  
 
4.2.4. Follow-up 
The follow-up period for identifying bladder cancer events was lagged to begin 180 days after 
the cohort entry date to allow for time between exposure and development of disease (induction 
period).(Figure 4.1) By excluding cases immediately following exposure, we thereby reduce the potential 
for spurious associations attributable to increased medicalization after start of a therapy or the 
possibility of preclinical symptoms of bladder cancer influencing treatment choice (protopathic bias). 
Patients who died or had the outcome within the first 180 days of follow-up were excluded from the 
analytic cohort. Two censoring approaches for follow-up were compared. The first approach, referred to 
here as the “as-treated” (AT) approach, continued until first occurrence of incident bladder cancer, 
death, disenrollment, study end (December 30, 2015), or treatment discontinuation (no subsequent 
dispensing for initiated drug class within days-supply plus a 90-day grace period). We added an 
additional 6-month latency period after treatment discontinuation to allow time for disease 
manifestation and detection. The second approach, referred to here as the “initial-treatment” (IT) 
approach, did not censor on treatment discontinuation, similar to the intent-to-treat approach used in 
randomized controlled trials. Although lag periods are typically applied following new use, we used the 
same lag period for the all user comparisons to be consistent across comparisons. Given that 
pioglitazone was on the market longer than some of the newer drugs, such as DPP-4i’s and SGLT-2i’s, 
follow-up was truncated at 5 years. We analyzed overall follow-up and follow-up stratified at two years, 
based on the original FDA safety warning. Only the subset of patients not otherwise censored within two 
years were included in analyses evaluating associations two years after cohort entry.  
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4.2.5. Covariates and Statistical Analysis 
The baseline covariate assessment period prior to cohort entry was 1 year (365 days). Covariates 
were selected a priori to include demographics (age, sex, and race), year of cohort entry, diabetes-
related complications (nephropathy, neuropathy, retinopathy), smoking, comorbidities, use of GLDs and 
other medications of interest. We used descriptive statistics to summarize covariates and to describe 
baseline differences across comparisons. The crude bladder cancer incidence rates (first event per 
patient) were calculated based on the Poisson distribution overall and for each treatment category. Cox 
proportional hazards models were used to estimate the Hazard Ratios (HR) and 95% Confidence 
Intervals (CI) for incident bladder cancer. Crude models included treatment as the only independent 
variable. Partially adjusted models included treatment, age, sex, race, and age-squared as independent 
variables. To be consistent with the 10-year safety study requested by the FDA,6 multivariable outcome 
regression models were used to obtain fully adjusted HRs. All data were analyzed in SAS, v9.4. The 
University of North Carolina at Chapel Hill institutional review board approved this study. 
 
4.3. Results 
Distribution of Patient Characteristics.  
Among the 1,510,212 patients who met the entry criteria for diabetes diagnosis, 135,188 were 
assigned to the pioglitazone Category 1 and 828,527 to the GLD Category 2 (Figure 4.2). Of the 
remaining patients, 124,100 had some GLD exposure (Category 3) and 422,397 were untreated 
(Category 4). A more detailed summary of the cohort and analytic cohort attrition for all comparisons 
can be found in Table 4.2. Among the all-user (Table 4.3) and new user (Table 4.4) comparisons, 
pioglitazone users were generally younger, but no appreciable difference in sex and race. Pioglitazone 
users were less likely to have a smoking-related claim, heart failure (HF) and prior use of loop diuretics. 
There were no clinically meaningful differences in urinary tract-related comorbidities across all 
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comparisons. Other comorbidities were similar for GLD and NIGLD comparisons, but less prevalent in 
pioglitazone users. In the all-user comparisons, pioglitazone users were generally more likely to have 
prior NIGLD use and diabetic complications. These differences were more pronounced when 
pioglitazone was compared to the non-pioglitazone group and for all new user comparisons, but 
characteristics were similar when compared to DPP-4i in the new user comparisons.  
Incidence of Bladder Cancer. 
Figure 4.3 illustrates the fully adjusted HRs for pioglitazone users compared to each referent 
group. Additional detail about the number of bladder cancer events and incidence rates per 100,000 
person-years, crude HRs, and HRs partially-adjusted for age, sex, and race are reported in Tables 4.5-
4.10. Overall, the incidence rates were fairly constant across all analyses ranging from 193.0-230.3 per 
100,000 person-years among the all-user comparisons and 188.6-251.0 per 100,000 in the new user 
comparisons, with the highest rates observed in the AT analyses. Given minimal differences in age, sex, 
and race across all comparisons, partially-adjusted HRs were generally similar to crude. When follow-up 
did not account for treatment changes, the HR ranged from 1.10 [95% CI: 1.01-1.20] to 1.13 [95% CI: 
0.99-1.29]. When cohorts restricted to new users, follow-up accounted for treatment changes, and DPP-
4i was used as the referent, the HR was 1.20 [95% CI: 1.01-1.42]. When follow-up was truncated at 2 
years, the HRs increased, the greatest increase identified among the IT analyses. For follow-up after 2 
years, there was a late-stage effect and a large increase in variance for all AT analyses as diabetic 
patients were less likely to stay on the same treatment for long durations, and HRs were generally 
attenuated for all comparisons except for pioglitazone versus DPP-4i, where the HR became larger.  
Exploration of the Components of the Non-pioglitazone Composite Referent Group. 
When we looked at some of the components of the non-pioglitazone referent group 
individually, the untreated patients represented 31% of the all-user and 62% of the new user composite 
non-pioglitazone referent groups. (Tables 4.11-4.12) Long-acting insulin users were more likely to have 
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diabetic complications than pioglitazone users, metformin users, and the untreated, respectively. New 
users of metformin were younger than new users of pioglitazone, new users of long-acting insulin, and 
the untreated, respectively. Other comorbidities were highest among the untreated and long-acting 
insulin groups. Bladder cancer rates for the non-pioglitazone referent group (193.8-195.9 per 100,000 
person-years) were similar to its untreated component (196.8 per 100,000 person-years), and higher 
than its metformin component (174.5-178.9 per 100,000 person-years). (Table 4.13-4.18) Fully-adjusted 
HRs for pioglitazone versus untreated were similar to pioglitazone versus the overall composite non-
pioglitazone referent group; these HRs were higher when compared to metformin and highest when 
compared to long-acting insulin. (Figure 4.4)  
 
4.4. Discussion and Conclusions 
Using the example of pioglitazone and bladder cancer among older adults, this paper highlights 
how effect estimates can change due to variation of study design choices. Although there are many 
publications outlining the importance of study design choices, including but not limited to those 
advocating for active comparator and new user designs,73,74,83-85 this paper is the first to systematically 
vary study design to compare effect estimates when evaluating the safety of a diabetic medication. 
Similar to the trends we identified in the existing literature on the association between pioglitazone and 
bladder cancer (Table 4.1) and as previously suggested,83,84 we found that estimates were generally 
lower when all users were included and when treatment changes were ignored, suggesting no increased 
risk. The HRs increased to 1.20 [95% CI: 1.01-1.42] when we restricted to new users, censored follow-up 
to accounted for treatment change, and used a clinically meaningful treatment alternative, DPP-4i, as 
the referent. Important differences were identified within the composite referent group of all non-
pioglitazone patients indicating that long-acting insulin users were at different stages of diabetic severity 
than pioglitazone users, metformin users, and the untreated, respectively.  
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There are many reasons for variation of published estimates. When we plotted the log of all 
relative estimates of the previously published studies against the precision of each study (Figure 4.5), we 
identified an asymmetrical pattern, which may be attributable to publication bias or selective outcome 
reporting, but is most likely due to the heterogeneity of study design choices.103 When studies do not 
restrict to new users of index treatment(s), estimates may adjust for variables affected by prior 
treatment, which can bias estimation of treatment effects toward the null and under-estimate harm.83,84 
Timing of outcome ascertainment is important especially for cancer outcomes given that the actual risk 
period relevant for drug-associated cancers is poorly understood.104 When treatment is defined at 
baseline ignoring treatment changes that occur during follow-up, estimates are more susceptible to 
exposure misclassification (via non-adherence), which can attenuate results towards the null, potentially 
masking drug effects on safety outcomes. Lastly, referent choice can also influence both the 
interpretation and generalizability of comparative safety estimates, because confounding by severity 
threatens study validity when there are major differences in disease severity between those prescribed 
the exposure and the referent.73 
Many of the published studies that evaluated the association between pioglitazone and bladder 
cancer used a composite referent group of all nonusers of pioglitazone. Therefore, we chose to include 
composite referent groups in this example to empirically demonstrate the impact of this approach on 
the effect estimates. Although the inclusion of all nonusers of the drug of interest in a referent group 
may increase power, effect estimates can be threatened by confounding by disease severity if there are 
major differences in disease severity between the drug of interest and the composite referent or its 
components.73,74 Furthermore, including untreated patients in the referent group can threaten validity 
further due to confounding by indication, since these patients are inherently different, especially if they 
either have less severe diabetes and are able to manage their diabetes without medical therapy (e.g., 
diet and exercise). As expected, the relative risk of bladder cancer for pioglitazone users compared to 
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patients who entered the composite non-pioglitazone group as metformin users was greater than that 
of pioglitazone compared to the entire non-pioglitazone referent group, because metformin is generally 
given at the earliest stage of diabetes severity per American Diabetes Association recommendation.105 
We had expected there to be a decreased risk of bladder cancer when pioglitazone users were 
compared to the long-acting insulin users, given previous literature9 and the increased frequency of 
diabetic complications among long-acting insulin users. However, the long-acting insulin users in our 
sample were at decreased risk of bladder cancer. This is mainly due to increased competing risk of death 
as they experienced differentially more deaths within the first 180 days after cohort entry. (Table 4.2) 
This study used a hierarchical exposure classification as was done previously,6 searching the 
entire study period of interest to first identify pioglitazone users, then subsequently identifying other 
GLD use among those without use of the GLD of interest, and then lastly identifying untreated based on 
no occurrence of treatment during the entire period. The benefit of this design is that all pioglitazone 
users are included in the primary exposure group. However, looking into the future to determine cohort 
entry may impose immortal person-time bias if there are patients who enter the pioglitazone group 
after treatment with another GLD that are subsequently excluded due to prevalent bladder cancer that 
may be attributed to the other treatment.106,107 In this example, the majority of patients classified as 
pioglitazone users in the all-user comparison had prior exposure to another GLD (Table 4.3), and ~1% of 
pioglitazone users with prior GLD use were excluded due to prevalent bladder cancer. Therefore, the 
hierarchical design excluded bladder cancer cases attributable to the other GLD, lowering the incidence 
rate among the referent group.  
This study has limitations that should be considered when interpreting results. First, although 
many of the design choices were implemented to be comparable to the 10-year safety study requested 
by the FDA,6 we were not able to completely emulate the previous study without a diabetic registry or 
10 years of follow-up, among other data differences. Second, we did not have access to pathological 
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confirmation of the bladder cancer outcome defined using claims. However, we used an algorithm 
previously validated for other solid tumors,91 and although we acknowledge potential misclassification, 
it is unlikely to be differential between treatment groups. Third, we did not have clinical records or 
biomarkers (e.g. HbA1c) necessary to determine diabetic severity, but evaluated codes for diabetic 
complications indicative of diabetic severity (neuropathy, nephropathy, and retinopathy) and adjusted 
for these. The new user comparisons that included multiple treatments had a substantial loss of power, 
but measured key covariates were balanced by design across treatment groups, also increasing the 
confidence about the balance of unmeasured covariates. Given that pioglitazone is often prescribed as 
second or in some cases third-line therapy, excluding prior use of any GLD among pioglitazone users 
excluded up to 96% of pioglitazone users, which increased the variance of the estimates. Excluding prior 
use of metformin excluded more than 50% of pioglitazone users. Fourth, a potential for detection bias 
has been suggested if pioglitazone users receive more urological work-up.108 However, since urinary 
tract-related comorbidities were similar across all comparisons, we do not suspect differentially more 
urological work-up among pioglitazone users. (Tables 4.19-5.20) Furthermore, we previously evaluated 
the rate of urologic diagnostic procedures and found no differences in initiators of pioglitazone 
compared with initiators of DPP-4i’s or sulfonylureas.19 Lastly, to allow comparison with previously 
reported estimates, we only report relative estimates. Given that the incidence of bladder cancer is low, 
absolute risks are consistently small. 
ACNU studies that exclude prevalent users and compare the initiation of the drug exposure of 
interest to the initiation of a clinically meaningful treatment alternative have been recommended for 
comparative effectiveness research to present the least biased comparison.73,74,85,87 If a composite 
referent group is necessary due to power concerns, we caution against inclusion of metformin 
monotherapy users, long-acting insulin users, and untreated diabetic patients. In our example, the DPP-
4i initiators were selected as the optimal comparator for pioglitazone initiators since DPP-4i’s are 
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prescribed to patients similar to those prescribed pioglitazone.19,78 Although an approach that ignores 
treatment changes may be added to present conservative estimates, AT estimates should be considered 
to minimize exposure misclassification. If there is reason to consider follow-up after end of exposure to 
allow for disease manifestation and diagnosis, such as with cancer outcomes, a latency period can be 
added to extend AT follow-up as necessary after treatment changes.89  
 Our study empirically demonstrates the effect of varying key parameters when evaluating the 
safety of diabetes drugs. The continued demand for new GLDs compels the need for more robust 
observational methods to improve the value of the RWE generation in order to equip clinicians to make 
informed prescribing decisions. Although there is no one-size-fits-all approach and recommendations 
may depend on the data source and the research question, we recommend that researchers consider 
how they define exposure, what they compare exposure to, and when they identify safety endpoints, as 




Table 4.1. Summary of Existing Literature  
Author Year Data Source New 
Use 








Estimate [95% CI] b 
Nissen 2008109 PERISCOPE  Yes RCT PIO/SU No No 0/270 1/273 RR, 0.33 [0.01-8.06] 
Erdmann 201614 PROactive  Yes RCT + Obs  PIO/Placebo No Yes 14/1820 21/1779 RR, 0.65 [0.33-1.28] 
Korhonen 201611 5 EU EHRs No Obs Co 
[Matched] 
PIO>4y/GLD No No 12/5809 153/56,337 aHR, 0.86 [0.44-1.66] 
Vallarino 20139 Optum  Yes Obs Co PIO/Insulin No No 84/38,588 44/17,948 aHR, 0.92 [0.63-1.33] 
Chang 201296 Taiwan NHIRD No Nested Ca-Co PIO/Non-PIO No No 84/401 1499/7490 aOR, 0.95 [0.70-1.29] 
Korhonen 201611 5 EU EHRs No Obs Co 
(Matched) 









aHR, 1.06 [0.89-1.26] 
Jin 2014100 Korean EMRs  No Nested Ca-Co PIO/Non-PIO No No 30/11,240 237/101,953 aHR, 1.14 [0.77-1.68] 
Mamtani 2012101 THIN Yes Obs Co PIO/ROSI No No 41/10,900 86/17,614 aHR, 1.14 [0.79-1.66] 
Wei 201310 CPRD Yes Obs Co PIO/NIGLD Unclear No 66/23,548 803/184,166 aHR, 1.16 [0.83-1.62] 
Lewis 20156 DM Registry No Nested Ca-Co PIO/Non-PIO No No 91/172 373/756 aOR, 1.18 [0.78-1.80] 
Kuo 201412 Taiwan NHIRD No Nested Ca-Co PIO/Non-PIO No No 15/67 244/1228 aOR, 1.20 [0.58-2.49] 
Lewis 201195 DM Registry No Obs Co PIO/Non-PIO No No 90/30,173 791/162,926 aHR, 1.2 [0.9-1.5] 
Garry 201719 Medicare Yes Obs Co PIO/DPP No Yes 282/ 
35,512 
308/70,628 aHR, 1.22[1.02-1.47] 





Wei 201310 CPRD Yes Obs Co 
(Matched) 
PIO/NIGLD Unclear No 39/17,249 48/17,249 aHR, 1.22[0.80-1.84] 
Bazelier 201398 Danish NH  No Obs Co 
(Matched) 
TZD/GLD No No 7/8121 2228/ 
485,319 
aHR, 1.28[0.61-1.70] 
Tseng 20127 Taiwan NHIRD No Obs Co PIO/GLD No No 10/2545 155/52,383 aHR, 1.31[0.66- 2.58] 
Lewis 201195 DM Registry Yes Obs Co PIO>2y/ 
Non-PIO 




aHR, 1.4 [1.03-2.0] 
Garry 201719 Medicare Yes Obs Co PIO/DPP Yes Yes 147/29,65
1 
193/61,438 aHR, 1.57 [1.23-2.00] 
Tuccori 201618 CPRD Yes Obs Co PIO/NIGLD No Yes 29/NP 497/142,758 aHR, 1.63 [1.22-2.19] 
Fujimoto 20128 Japan NH No Obs Co PIO/Non-PIO No No 9/663 161/20,672 aHR, 1.75 [0.89-3.45] 
Tuccori 201618 CPRD Yes Obs Co PIO>2y/NIGL
D 









Author Year Data Source New 
Use 











[95% CI] b 
Azoulay 201216 CPRD Yes Nested Ca-Co PIO/ 
Never TZD 
No Yes 19/210 319/6175 IRR, 1.83 [1.10-3.05] 
Jin 2014100 Korean EMRs  No Nested Ca-Co PIO>6m/ 
Non-PIO 
No No 22/61 182/741 aHR, 1.97[1.02-3.80] 
Azoulay 201216 CPRD Yes Nested Ca-Co PIO>2y/ 
Never TZD 
No Yes 16/169 319/6175 IRR, 1.99 [1.14-3.45] 
Mamtani 
2012101 
THIN Yes Obs Co PIO>5y/PIO 
<1y 
No No 4/NP 17/NP aHR, 2.05 [0.67-6.32] 
Song 201297 Korean EMR No Ca-Co PIO/ 
Non-PIO 
No No 21/120 308/867 aOR, 2.09 [0.26-16.8] 
Dormandy 
200534 
PROactive RCT Yes RCT PIO/Placebo No No 14/2605 6/2633 RR, 2.36 [0.91-6.13] 
Hsiao 201399 Taiwan NHIRD No Nested Ca-Co PIO/Non-PIO No No 82/262 3259/19,796 aOR, 2.39 [1.75-3.25] 
Piccinni 201176 FDA AERs No Case/Noncas
e  
PIO/GLD No No 31/37,872 107/561,351 OR, 4.30 [2.82-6.52] 
Tolman 2009110 Trial Data Yes RCT PIO/SU No No 2/1051 0/1046 RR, 4.98 [0.24-103.5] 
CPRD, Clinical Practice Research Datalink; DM, Diabetes Mellitus; Ca-Co, Case-Control; Co, Cohort; Exp, Exposure; Obs, Observational; NH, National Health; 
NHIRD, National Health Insurance Research Database; Obs, Observational; PERISCOPE, Prospective Evaluation of a RIsk Score for postoperative pulmonary 
COmPlications in Europe; PROactive, PROspective pioglitAzone Clinical Trial In macroVascular Events; Ref, Referent; RCT, Randomized Controlled Trial; ROSI, 
Rosiglitazone; SU, Sulfonylureas 
a. Assessment of whether or not follow-up accounted for treatment changes (e.g. index drug discontinuation) or incorporated a lag and/or latency period; b. 
For trials that provided only the number of cases, risk ratios and confidence intervals were manually calculated. If any cell size was 0, 0.5 was added to all 
cells in order to calculate the estimates 
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Table 4.2. Summary of cohort and analytic cohort attrition  
 COHORT ANALYTIC COHORT 
 Included Excluded Included Excluded (Censor Event During Lag) 
 N Current Use N Outcome Death End PartD 
ALL USER COMPARISONS  
PIO vs. Non-PIO  1,510,212  
N/A 
 1,376,395  -0.1% -6.1% -2.6% 
PIO  135,188   129,539  -0.1% -2.0% -2.1% 
Non-PIO  1,375,024   1,246,856  -0.1% -6.5% -2.7% 
PIO vs. All GLDs  963,715   910,707  -0.1% -3.3% -2.1% 
PIO  135,188   129,539  -0.1% -2.0% -2.1% 
GLD  828,527   781,168  -0.1% -3.5% -2.1% 
PIO vs. All NIGLDs  840,634   799,910  -0.1% -2.6% -2.1% 
PIO  135,188   129,539  -0.1% -2.0% -2.1% 
NIGLD  705,446   670,371  -0.1% -2.7% -2.2% 
PIO vs. DPP  263,277   250,797  -0.1% -2.5% -2.1% 
PIO  135,188   129,539  -0.1% -2.0% -2.1% 
DPP  128,089   121,258  -0.1% -3.0% -2.2% 
PIO vs. LA Insulin  406,067   377,214  -0.1% -4.9% -2.1% 
PIO  135,188   129,539  -0.1% -2.0% -2.1% 
LA INSULIN  270,879   247,675  -0.1% -6.3% -2.2% 
PIO vs. MET  611,422   584,451  -0.1% -2.1% -2.2% 
PIO  135,188   129,539  -0.1% -2.0% -2.1% 
MET  476,234   454,912  -0.1% -2.1% -2.2% 
PIO vs. Untreated  557,585   504,491  -0.1% -7.2% -2.2% 
PIO  135,188   129,539  -0.1% -2.0% -2.1% 
Untreated  422,397   374,952  -0.1% -8.8% -2.3% 
NEW USER COMPARISONS 
PIO vs. Non-PIO  681,738  -55%  608,001  -0.1% -8.0% -2.7% 
PIO  5,752  -96%  5,468  -0.1% -2.4% -2.4% 
Non-PIO  675,986  -51%  602,462  -0.1% -8.1% -2.7% 
PIO vs. All GLDs  178,415  -81%  166,537  -0.1% -4.3% -2.2% 
PIO  5,752  -96%  5,468  -0.1% -2.4% -2.4% 
GLD  172,663  -79%  161,172  -0.1% -4.4% -2.2% 
PIO vs. All NIGLDs  182,059  -78%  171,363  -0.1% -3.5% -2.2% 
PIO  7,547  -94%  7,116  -0.1% -3.3% -2.4% 
NIGLD  174,512  -75%  164,247  -0.1% -3.5% -2.2% 
PIO vs. DPP  110,054  -58%  103,717  -0.1% -3.3% -2.3% 
PIO  33,551  -75%  31,809  -0.1% -2.7% -2.4% 
DPP  76,503  -40%  71,908  -0.1% -3.6% -2.3% 
PIO vs. LA Insulin  24,452  -94%  21,642  -0.1% -9.1% -2.3% 
PIO  5,752  -96%  5,468  -0.1% -2.4% -2.4% 
LA INSULIN  18,700  -93%  16,174  -0.1% -11.1% -2.2% 
PIO vs. MET  105,582  -83%  101,084  -0.1% -2.0% -2.2% 
PIO  5,752  -96%  5,468  -0.1% -2.4% -2.4% 
MET  99,830  -79%  95,616  -0.1% -2.0% -2.2% 
PIO vs. Untreated  428,149  -23%  380,420  -0.1% -8.8% -2.3% 
PIO  5,752  -96%  5,468  -0.1% -2.4% -2.4% 
Untreated  422,397  -0%  374,952  -0.1% -8.8% -2.3% 
DPP-4i, Dipeptidyl peptidase-4 inhibitors; GLD, Glucose-Lowering Drug; LA, Long-Acting; MET, 





Table 4.3. Summary of cohort and analytic cohort attrition Distribution (%) of patient characteristics 
among pioglitazone users & each referent (All User)  
A. Non-pioglitazone and glucose-lowering drug (GLD) referent groups 
 PIO Non-PIO PIO GLD 
N 135,188 1,375,024 135,188 828,527 
Demographics and Lifestyle at Cohort Entry     
Age, mean (SD) 74.7 (6.7) 75.9 (7.7) 74.7 (6.7) 74.9 (7.3) 
Age, median (IQR) 73 (69,79) 74 (69,81) 73 (69,79) 73 (69,80) 
Male 43.6 40.3 43.6 41.3 
White 74.3 78.7 74.3 78.5 
Black 11.7 12.4 11.7 12.8 
Other Race (Asian, Hispanic, or Native American) 14.0 8.9 14.0 8.7 
Index Year: 2008 50.6 34.7 50.6 41.3 
Index Year: 2009 12.1 9.1 12.1 7.3 
Index Year: 2010 11.1 8.0 11.1 6.7 
Index Year: 2011 8.2 8.4 8.2 7.3 
Index Year: 2012 4.2 8.7 4.2 7.9 
Index Year: 2013 4.1 9.4 4.1 8.8 
Index Year: 2014 6.8 14.1 6.8 13.8 
Index Year: 2015 2.9 7.7 2.9 6.9 
Smoking a 7.7 12.3 7.7 11.4 
Diabetic Complications     
Nephropathy 8.4 6.0 8.4 7.7 
Neuropathy 19.5 13.3 19.5 18.0 
Retinopathy 19.3 10.6 19.3 15.5 
Diabetic Medication Use     
Thiazolidinediones 69.1 5.2 69.1 7.9 
Dipeptidyl-peptidase-4 Inhibitors 11.3 4.8 11.3 7.6 
Metformin 57.3 29.6 57.3 46.9 
Sulfonylureas 51.0 22.8 51.0 36.0 
Other b 6.8 2.8 6.8 4.4 
Sodium-GLucose co-Transporter-2 inhibitors 0.2 0.1 0.2 0.1 
Fast-Acting Insulin 6.9 8.2 6.9 12.4 
Long-Acting Insulin 16.8 15.6 16.8 23.8 
Other Co-morbidities     
Heart Failure  15.6 23.0 15.6 21.8 
Chronic Obstructive Pulmonary Disease  14.1 19.9 14.1 18.0 
Myocardial Infarction  0.7 1.1 0.7 1.1 
Stroke 10.0 12.9 10.0 11.9 
History of Cancer d 16.5 20.7 16.5 17.9 
Medication Use     
Angiotensin-converting enzyme inhibitor  42.3 37.0 42.3 40.8 
Angiotensin receptor blockers  18.5 15.8 18.5 16.5 
Beta Blockers 42.7 47.3 42.7 47.5 
Calcium Channel Blocker  29.1 31.3 29.1 31.0 
Loop Diuretics 23.7 27.4 23.7 28.2 
Statins 66.2 51.1 66.2 54.8 
GLD, Glucose-Lowering Drug; PIO, Pioglitazone  
a. Smoking was defined using a validated algorithm that has nearly perfect specificity and PPV, but poor 
sensitivity (27.9% [95% CI: 16.6-39.1%]);111b. Other diabetic medications included alpha-glucosidase inhibitors, 
amylin analogs, glucagon-like peptide-1 receptor agonists, & meglitinides. 
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B. Glucose-lowering drug (GLD) and non-insulin GLD referent groups 
 PIO NIGLD PIO DPP 
N 135,188 705,446 135,188 128,089 
Demographics and Lifestyle at Cohort Entry     
Age, mean (SD) 74.7 (6.7) 74.8 (7.2) 74.7 (6.7) 75.2 (7.1) 
Age, median (IQR) 73 (69,79) 73 (69,80) 73 (69,79) 74 (69,80) 
Male 43.6 41.7 43.6 41.8 
White 74.3 79.1 74.3 77.5 
Black 11.7 11.9 11.7 11.3 
Other Race (Asian, Hispanic, or Native American) 14.0 9.1 14.0 11.2 
Index Year: 2008 50.6 39.3 50.6 13.8 
Index Year: 2009 12.1 7.6 12.1 7.4 
Index Year: 2010 11.1 7.0 11.1 8.2 
Index Year: 2011 8.2 7.6 8.2 11.6 
Index Year: 2012 4.2 8.1 4.2 13.5 
Index Year: 2013 4.1 9.1 4.1 14.8 
Index Year: 2014 6.8 14.3 6.8 21.0 
Index Year: 2015 2.9 7.0 2.9 9.7 
Smoking a 7.7 11.1 7.7 13.1 
Diabetic Complications     
Nephropathy 8.4 5.8 8.4 10.3 
Neuropathy 19.5 15.9 19.5 22.6 
Retinopathy 19.3 13.2 19.3 17.3 
Diabetic Medication Use     
Thiazolidinediones 69.1 8.2 69.1 8.7 
Dipeptidyl-peptidase-4 Inhibitors 11.3 8.4 11.3 35.1 
Metformin 57.3 52.8 57.3 62.5 
Sulfonylureas 51.0 40.1 51.0 49.2 
Other b 6.8 4.7 6.8 6.4 
Sodium-GLucose co-Transporter-2 inhibitors 0.2 0.2 0.2 0.4 
Fast-Acting Insulin 6.9 7.4 6.9 8.4 
Long-Acting Insulin 16.8 15.6 16.8 18.1 
Other Co-morbidities     
Heart Failure  15.6 18.8 15.6 23.0 
Chronic Obstructive Pulmonary Disease  14.1 16.7 14.1 17.7 
Myocardial Infarction  0.7 0.9 0.7 1.1 
Stroke 10.0 10.6 10.0 11.8 
History of Cancer d 16.5 18.0 16.5 21.7 
Medication Use     
Angiotensin-converting enzyme inhibitor  42.3 40.3 42.3 39.7 
Angiotensin receptor blockers  18.5 16.1 18.5 19.8 
Beta Blockers 42.7 46.2 42.7 50.6 
Calcium Channel Blocker  29.1 30.1 29.1 32.4 
Loop Diuretics 23.7 25.1 23.7 28.5 
Statins 66.2 55.1 66.2 56.7 
DPP-4i, Dipeptidyl peptidase-4 inhibitors; NIGLD, Non-Insulin Glucose-Lowering Drug; PIO, Pioglitazone  
a. Smoking was defined using a validated algorithm that has nearly perfect specificity and PPV, but poor 
sensitivity (27.9% [95% CI: 16.6-39.1%]);111 b. Other diabetic medications included alpha-glucosidase 





Table 4.4. Distribution (%) of patient characteristics among initiators of pioglitazone & each referent 
(new user design)  
A. Non-pioglitazone and glucose-lowering drug (GLD) referent groups 
 PIO* Non-PIO PIO* GLD 
N 5,752 675,986 5,752 172,663 
Demographics and Lifestyle at Cohort Entry     
Age, mean (SD) 75.4 (6.9) 76.8 (7.8) 75.4 (6.9) 75.2 (7.1) 
Age, median (IQR) 74 (70,80) 76 (70,83) 74 (70,80) 74 (69,80) 
Male 45.0 39.4 45.0 42.8 
White 70.4 79.5 70.4 79.4 
Black 11.8 11.3 11.8 11.2 
Other Race (Asian, Hispanic, or Native American) 17.8 9.2 17.8 9.5 
Index Year: 2008 26.5 20.3 26.5 12.8 
Index Year: 2009 22.3 12.7 22.3 13.9 
Index Year: 2010 16.2 11.1 16.2 12.9 
Index Year: 2011 11.0 11.0 11.0 12.4 
Index Year: 2012 4.9 10.6 4.9 11.8 
Index Year: 2013 5.4 11.1 5.4 11.9 
Index Year: 2014 5.9 14.0 5.9 13.0 
Index Year: 2015 7.7 9.3 7.7 11.3 
Smoking a 9.2 13.5 9.2 13.7 
Diabetic Complications     
Nephropathy 5.8 2.8 5.8 3.8 
Neuropathy 10.1 5.5 10.1 8.3 
Retinopathy 8.0 3.0 8.0 5.2 
Diabetic Medication Use     
Thiazolidinediones -- --  --  --  
Dipeptidyl-peptidase-4 Inhibitors -- --  --  --  
Metformin -- --  --  --  
Sulfonylureas -- --  --  --  
Other b -- --  --  --  
Sodium-GLucose co-Transporter-2 inhibitors -- --  --  --  
Fast-Acting Insulin -- --  --  --  
Long-Acting Insulin -- --  --  --  
Other Co-morbidities     
Heart Failure  15.0 22.9 15.0 20.5 
Chronic Obstructive Pulmonary Disease  16.9 21.7 16.9 20.0 
Myocardial Infarction  0.8 1.2 0.8 1.1 
Stroke 10.6 13.5 10.6 12.1 
History of Cancer d 18.8 24.4 18.8 22.4 
Medication Use     
Angiotensin-converting enzyme inhibitor  29.4 30.5 29.4 31.9 
Angiotensin receptor blockers  15.0 14.2 15.0 13.5 
Beta Blockers 1.4 1.6 1.4 1.5 
Calcium Channel Blocker  28.9 31.5 28.9 30.6 
Loop Diuretics 19.7 25.0 19.7 24.3 
Statins 50.3 45.5 50.3 46.9 
GLD, Glucose-Lowering Drug; PIO, Pioglitazone  
a. Smoking was defined using a validated algorithm that has nearly perfect specificity and PPV, but poor 
sensitivity (27.9% [95% CI: 16.6-39.1%]);111 b. Other diabetic medications included alpha-glucosidase inhibitors, 
amylin analogs, glucagon-like peptide-1 receptor agonists, & meglitinides. 
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B. Glucose-lowering drug (GLD) and non-insulin GLD referent groups 
 PIO* NIGLD PIO* DPP 
N 7,547 174,512 33,551 76,503 
Demographics and Lifestyle at Cohort Entry     
Age, mean (SD) 75.4 (6.9) 75.0 (7.0) 74.9 (6.7) 75.7 (7.1) 
Age, median (IQR) 74 (70,80) 73 (69,80) 74 (69,79) 74 (70,81) 
Male 43.7 42.2 42.7 39.5 
White 68.8 79.4 72.5 76.7 
Black 14.0 11.1 11.7 11.1 
Other Race (Asian, Hispanic, or Native American) 17.2 9.6 15.9 12.3 
Index Year: 2008 26.0 12.6 23.2 7.7 
Index Year: 2009 22.7 13.8 24.1 9.0 
Index Year: 2010 16.9 12.8 19.4 10.1 
Index Year: 2011 11.1 12.5 11.6 14.2 
Index Year: 2012 4.9 12.0 4.6 15.8 
Index Year: 2013 5.6 12.2 5.7 15.9 
Index Year: 2014 5.9 13.6 6.7 17.2 
Index Year: 2015 6.9 10.6 4.6 10.2 
Smoking a 9.4 13.4 9.0 13.8 
Diabetic Complications     
Nephropathy 8.9 4.4 8.5 10.2 
Neuropathy 16.0 10.4 19.3 22.6 
Retinopathy 13.3 7.2 16.6 16.3 
Diabetic Medication Use     
Thiazolidinediones --  --  --  --  
Dipeptidyl-peptidase-4 Inhibitors --  --  --  --  
Metformin --  --  60.3 61.7 
Sulfonylureas --  --  53.4 49.6 
Other b --  --  5.4 5.6 
Sodium-GLucose co-Transporter-2 inhibitors --  --  0.2 0.2 
Fast-Acting Insulin 13.3 8.2 8.2 9.1 
Long-Acting Insulin 25.1 13.3 16.3 17.4 
Other Co-morbidities     
Heart Failure  19.1 20.0 16.7 24.9 
Chronic Obstructive Pulmonary Disease  18.8 19.4 15.8 19.4 
Myocardial Infarction  0.8 1.1 0.8 1.2 
Stroke 12.6 11.6 11.4 12.9 
History of Cancer d 19.6 22.2 19.8 24.2 
Medication Use     
Angiotensin-converting enzyme inhibitor  32.5 33.2 42.2 40.3 
Angiotensin receptor blockers  15.8 14.1 16.7 19.3 
Beta Blockers 1.5 1.5 1.6 2.1 
Calcium Channel Blocker  31.0 30.7 31.7 34.0 
Loop Diuretics 25.0 25.0 22.1 29.5 
Statins 51.7 48.3 59.6 55.5 
DPP-4i, Dipeptidyl peptidase-4 inhibitors; NIGLD, Non-Insulin Glucose-Lowering Drug; PIO, Pioglitazone  
a. Smoking was defined using a validated algorithm that has nearly perfect specificity and PPV, but poor 
sensitivity (27.9% [95% CI: 16.6-39.1%]);111 b. Other diabetic medications included alpha-glucosidase 






Table 4.5. Bladder cancer incidence among pioglitazone users compared to each referent  (All-User: Overall Follow-up) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses 
PIO vs. non-PIO PIO  4.13(1.66-4.93)  129,539   960  221.6  1.14(1.06-1.22) 1.13(1.05-1.21) 1.10(1.01-1.20) 
 non-PIO 2.36(1.02-4.86) 1,247,157  6,372  194.9   
PIO vs. GLD PIO  4.13(1.66-4.93)  129,539   960  221.6  1.14(1.07-1.23) 1.13(1.05-1.21) 1.08(0.99-1.19) 
 GLD 2.49(1.10-4.93)  781,168   4,123  194.1   
PIO vs. NIGLD PIO  4.13(1.66-4.93)  129,539   960  221.6  1.15(1.07-1.23) 1.14(1.06-1.22) 1.10(1.00-1.20) 
 NIGLD 2.58(1.12-4.93)  670,371   3,562  193.0   
PIO vs. DPP PIO  4.13(1.66-4.93)  129,539   960  221.6  1.13(1.02-1.26) 1.12(1.01-1.25) 1.13(0.99-1.29) 
 DPP 1.97(0.93-3.68)  121,258   550  198.1   
 As-Treated Analyses 
PIO vs. non-PIO PIO  1.58(0.99-3.03)  129,539   621  230.3  1.19(1.09-1.29) 1.18(1.09-1.28) 1.18(1.06-1.32) 
 non-PIO 1.75(0.90-3.71) 1,247,157   5,443  193.8    
PIO vs. GLD PIO  1.58(0.99-3.03)  129,539   621  230.3  1.19(1.09-1.30) 1.17(1.08-1.28) 1.16(1.04-1.30) 
 GLD 1.65(0.97-3.38)  781,168   3,274  192.6    
PIO vs. NIGLD PIO  1.58(0.99-3.03)  129,539   621  230.3  1.20(1.10-1.31) 1.20(1.10-1.31) 1.18(1.05-1.32) 
 NIGLD 1.57(0.94-3.21)  670,371   2,707  191.3    
PIO vs. DPP PIO  1.58(0.99-3.03)  129,539   621  230.3  1.14(1.01-1.29) 1.13(1.00-1.29) 1.20(1.01-1.42) 
 DPP 1.24(0.82-2.25)  121,258   409  202.5   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end of 
enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-
supply plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-treated 
analyses additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. All follow-up 
was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-day 
induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each new 
user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts for 
age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), smoking, 
HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, TZDs, DPP-4s, 







Table 4.6. Bladder cancer incidence among pioglitazone users compared to each referent  (New user: Overall Follow-up) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses 
PIO vs. non-PIO PIO  3.76(1.38-4.93)  5,468   38  221.5 1.13(0.82-1.55) 1.12(0.81-1.54) 1.16(0.83-1.63) 
 non-PIO 2.23(0.89-4.35)  602,642   2,947  195.9   
PIO vs. GLD PIO  3.76(1.38-4.93)  5,468   38  221.5 1.13(0.82-1.56) 1.14(0.82-1.57) 1.16(0.82-1.64) 
 GLD 2.26(0.88-4.23)  161,172   789  197.0   
PIO vs. NIGLD PIO  3.44(1.31-4.93)  7,116   45  207.6 1.06(0.78-1.43) 1.07(0.79-1.44) 1.07(0.77-1.47) 
 NIGLD 2.28(0.92-4.24)  164,247   810  197.0   
PIO vs. DPP PIO  3.72(1.48-4.93)  31,809   222  220.6 1.17(0.98-1.39) 1.17(0.98-1.39) 1.15(0.95-1.40) 
 DPP 2.02(0.85-3.61)  71,908   309  188.6  
 As-Treated Analyses 
PIO vs. non-PIO PIO  1.24(0.83-2.22)  5,468   23  251.0  1.29(0.86-1.95) 1.29(0.85-1.94) 1.37(0.89-2.10) 
 non-PIO 1.79(0.82-3.88)  602,642   2,675  195.4    
PIO vs. GLD PIO  1.24(0.83-2.22)  5,468   23  251.0  1.28(0.84-1.95) 1.29(0.85-1.95) 1.34(0.86-2.09) 
 GLD 1.33(0.82-2.63)  161,172   570  194.0    
PIO vs. NIGLD PIO  1.22(0.83-2.09)  7,116   27  235.0  1.20(0.82-1.77) 1.21(0.82-1.79) 1.22(0.81-1.84) 
 NIGLD 1.32(0.82-2.58)  164,247   577  194.3    
PIO vs. DPP PIO  1.28(0.90-2.21)  31,809   132  244.8  1.27(1.03-1.58) 1.26(1.02-1.57) 1.31(1.03-1.68) 
 DPP 1.22(0.82-2.20)  71,908   223  191.8   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end of 
enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-supply 
plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-treated analyses 
additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. All follow-up was 
truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-day 
induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each new user 
comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts for age, 
age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), smoking, HF, MI, 
Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, TZDs, DPP-4i’s, 







Table 4.7. Bladder cancer incidence among pioglitazone users compared to each referent  (All-user: Follow-up ≤2 Years) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses 
PIO vs. non-PIO PIO  1.97(1.66-1.97)  129,539   489  225.4  1.18(1.08-1.30) 1.19(1.08-1.30) 1.16(1.03-1.31) 
 non-PIO 1.97(1.02-1.97) 1,247,157   3,538  190.7   
PIO vs. GLD PIO  1.97(1.66-1.97)  129,539   489  225.4  1.17(1.06-1.29) 1.16(1.05-1.28) 1.13(1.00-1.28) 
 GLD 1.97(1.10-1.97)  781,168   2,290  193.1   
PIO vs. NIGLD PIO  1.97(1.66-1.97)  129,539   489  225.4  1.17(1.06-1.30) 1.17(1.06-1.29) 1.14(1.00-1.29) 
 NIGLD 1.97(1.12-1.97)  670,371   1,969  192.2   
PIO vs. DPP PIO  1.97(1.66-1.97)  129,539   489  225.4  1.10(0.96-1.26) 1.10(0.96-1.27) 1.09(0.91-1.31) 
 DPP 1.97(0.93-1.97)  121,258   358  206.2   
 As-Treated Analyses 
PIO vs. non-PIO PIO  1.58(0.99-1.97)  129,539   425  227.8  1.19(1.07-1.31) 1.19(1.07-1.31) 1.18(1.04-1.35) 
 non-PIO 1.75(0.90-1.97) 1,247,157   3,355  191.3    
PIO vs. GLD PIO  1.58(0.99-1.97)  129,539   425  227.8  1.17(1.06-1.30) 1.16(1.04-1.29) 1.14(1.00-1.31) 
 GLD 1.65(0.97-1.97)  781,168   2,137  194.1    
PIO vs. NIGLD PIO  1.58(0.99-1.97)  129,539   425  227.8  1.18(1.06-1.31) 1.17(1.06-1.30) 1.15(1.01-1.32) 
 NIGLD 1.57(0.94-1.97)  670,371   1,809  193.2    
PIO vs. DPP PIO  1.58(0.99-1.97)  129,539   425  227.8  1.10(0.95-1.27) 1.10(0.95-1.27) 1.14(0.93-1.38) 
 DPP 1.24(0.82-1.97)  121,258   319  208.5   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or 
end of enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class 
within days-supply plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. 
The as-treated analyses additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of 
patient data. All follow-up was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-
day induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in 
each new user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts 
for age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), 
smoking, HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, 






Table 4.8. Bladder cancer incidence among pioglitazone users compared to each referent  (New user: Follow-up ≤2 Years) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses 
PIO vs. non-PIO PIO  1.97(1.38-1.97)  5,468   21  239.5 1.27(0.83-1.95) 1.28(0.83-1.97) 1.41(0.90-2.20) 
 non-PIO 1.97(0.89-1.97)  602,642   1,659  189.3   
PIO vs. GLD PIO  1.97(1.38-1.97)  5,468   21  239.5 1.21(0.78-1.88) 1.22(0.79-1.89) 1.30(0.83-2.05) 
 GLD 1.97(0.88-1.97)  161,172   466  198.5   
PIO vs. NIGLD PIO  1.97(1.31-1.97)  7,116   26  230.3 1.17(0.79-1.73) 1.17(0.79-1.74) 1.20(0.80-1.82) 
 NIGLD 1.97(0.92-1.97)  164,247   478  198.2   
PIO vs. DPP PIO  1.97(1.48-1.97)  31,809   113  217.4 1.15(0.91-1.45) 1.16(0.92-1.46) 1.17(0.90-1.53) 
 DPP 1.97(0.85-1.97)  71,908   197  191.0  
 As-Treated Analyses 
PIO vs. non-PIO PIO  1.24(0.83-1.97)  5,468   18  257.6  1.35(0.85-2.15) 1.37(0.86-2.17) 1.49(0.92-2.41) 
 non-PIO 1.79(0.82-1.97)  602,642   1,588  189.7    
PIO vs. GLD PIO  1.24(0.83-1.97)  5,468   18  257.6  1.28(0.80-2.06) 1.29(0.80-2.06) 1.37(0.83-2.23) 
 GLD 1.33(0.82-1.97)  161,172   415  199.9    
PIO vs. NIGLD PIO  1.22(0.83-1.97)  7,116   21  234.6  1.18(0.76-1.83) 1.20(0.77-1.85) 1.22(0.77-1.93) 
 NIGLD 1.32(0.82-1.97)  164,247   419  198.0    
PIO vs. DPP PIO  1.28(0.90-1.97)  31,809   95  227.9  1.17(0.91-1.51) 1.18(0.92-1.52) 1.23(0.92-1.64) 
 DPP 1.22(0.82-1.97)  71,908   173  194.1   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end 
of enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within 
days-supply plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-
treated analyses additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. 
All follow-up was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-
day induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each 
new user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts 
for age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), 
smoking, HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, 






Table 4.9. Bladder cancer incidence among pioglitazone user compared to each referent  (All-user: Follow-up >2 Years) 
 ALL USER COMPARISONS (PREVALENT USERS INCLUDED) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses 
PIO vs. non-PIO PIO  2.96(1.77-2.96)  93,199   471  217.8  1.09(0.99-1.20) 1.07(0.97-1.18) 1.04(0.91-1.18) 
 non-PIO 2.46(1.09-2.96)  700,680   2,834  200.3   
PIO vs. GLD PIO  2.96(1.77-2.96)  93,199   471  217.8  1.12(1.01-1.23) 1.09(0.99-1.21) 1.04(0.91-1.18) 
 GLD 2.64(1.14-2.96)  455,789   1,833  195.3   
PIO vs. NIGLD PIO  2.96(1.77-2.96)  93,199   471  217.8  1.12(1.01-1.24) 1.11(1.00-1.23) 1.06(0.93-1.21) 
 NIGLD 2.68(1.15-2.96)  396,641   1,593  194.1   
PIO vs. DPP PIO  2.96(1.77-2.96)  93,199   471  217.8  1.18(0.99-1.39) 1.15(0.97-1.36) 1.17(0.95-1.43) 
 DPP 1.71(0.73-2.96)  60,618   192  184.5   
 As-Treated Analyses 
PIO vs. non-PIO PIO  1.44(0.56-2.63)  53,509   196  235.9  1.19(1.02-1.37) 1.16(1.00-1.35) 1.18(0.96-1.44) 
 non-PIO 1.97(0.79-2.96)  578,542   2,088  198.1    
PIO vs. GLD PIO  1.44(0.56-2.63)  53,509   196  235.9  1.24(1.07-1.44) 1.21(1.04-1.40) 1.19(0.97-1.47) 
 GLD 1.75(0.67-2.96)  345,532   1,137  189.9    
PIO vs. NIGLD PIO  1.44(0.56-2.63)  53,509   196  235.9  1.26(1.08-1.47) 1.25(1.07-1.46) 1.22(0.98-1.52) 
 NIGLD 1.63(0.62-2.96)  284,625   898  187.6    
PIO vs. DPP PIO  1.44(0.56-2.63)  53,509   196  235.9  1.28(1.00-1.65) 1.23(0.96-1.58) 1.38(0.96-1.97) 
 DPP 1.11(0.41-2.23)  36,774   90  183.6   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end of 
enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-
supply plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-treated 
analyses additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. All follow-
up was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-day 
induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each new 
user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts for 
age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), smoking, 
HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, TZDs, DPP-






Table 4.10. Bladder cancer incidence among pioglitazone user compared to each referent  (New user: Follow-up >2 Years) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses 
PIO vs. non-PIO PIO  2.93(1.67-2.96)  3,715   17  202.6 0.99(0.61-1.60) 0.96(0.60-1.56) 0.92(0.54-1.57) 
 non-PIO 2.06(0.94-2.96)  88,227   323  194.8   
PIO vs. GLD PIO  2.81(1.51-2.96)  4,707   19  182.9 1.04(0.64-1.69) 1.04(0.64-1.69) 1.00(0.58-1.72) 
 GLD 2.05(0.93-2.96)  90,681   332  195.4   
PIO vs. NIGLD PIO  2.84(1.57-2.96)  21,876   109  224.0 0.94(0.59-1.49) 0.94(0.59-1.50) 0.91(0.54-1.51) 
 NIGLD 1.60(0.74-2.85)  36,613   112  184.4   
PIO vs. DPP PIO  2.93(1.67-2.96)  3,715   17  202.6 1.20(0.92-1.56) 1.18(0.90-1.54) 1.13(0.85-1.51) 
 DPP 2.06(0.94-2.96)  88,227   323  194.8  
 As-Treated Analyses 
PIO vs. non-PIO PIO  1.15(0.47-2.29)  1,587   <11  229.9  1.11(0.46-2.68) 1.08(0.45-2.59) 1.03(0.39-2.75) 
 non-PIO 2.07(0.88-2.96)  284,196   1,087  204.4    
PIO vs. GLD PIO  1.15(0.47-2.29)  1,587   <11  229.9  1.28(0.53-3.12) 1.28(0.53-3.12) 1.25(0.46-3.39) 
 GLD 1.37(0.55-2.66)  56,361   155  180.0    
PIO vs. NIGLD PIO  1.07(0.43-2.17)  1,930   <11  236.4  1.28(0.57-2.90) 1.27(0.56-2.87) 1.25(0.50-3.09) 
 NIGLD 1.34(0.54-2.61)  56,625   158  185.0    
PIO vs. DPP PIO  1.07(0.42-2.17)  9,339   37  302.3  1.64(1.07-2.50) 1.54(1.00-2.36) 1.56(0.97-2.52) 
 DPP 1.07(0.43-2.07)  20,975   50  184.4   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end of 
enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-
supply plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-treated 
analyses additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. All follow-
up was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-day 
induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each new 
user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts for 
age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), smoking, 
HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, TZDs, DPP-
4i’s, metformin, sulfonylureas, SGLT-2i’s, fast-acting insulin, long-acting insulin, other glucose-lowering drugs. 
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Table 4.11. Distribution (%) of patient characteristics among the components of the non-pioglitazone 
referent group (All User) 
PIO LA INSULIN PIO MET PIO Untreated 
N  135,188  270,879  135,188   476,234  135,188 422,397  
Demographics and Lifestyle at Cohort Entry 
Age, mean (SD) 74.7 (6.7)  75.6 (7.4) 74.7 (6.7)  74.1 (6.7) 74.7 (6.7)  77.7 (8.0) 
Age, median (IQR) 73 (69,79) 74 (69,81) 73 (69,79) 73 (69,78) 73 (69,79) 77 (71,84) 
Male 43.6 39.8 43.6 41.6 43.6 36.5 
White 74.3 76.8 74.3 79.7 74.3 80.3 
Black 11.7 15.4 11.7 10.9 11.7 10.8 
Other (Asian, Hispanic, or 
Native American) 14.0 7.8 14.0 9.3 14.0 8.9 
Index Year: 2008 50.6 40.1 50.6 32.7 50.6 23.1 
Index Year: 2009 12.1 8.4 12.1 8.5 12.1 12.4 
Index Year: 2010 11.1 7.2 11.1 8.2 11.1 10.7 
Index Year: 2011 8.2 7.8 8.2 8.6 8.2 10.7 
Index Year: 2012 4.2 8.4 4.2 9.0 4.2 10.4 
Index Year: 2013 4.1 9.1 4.1 10.3 4.1 10.8 
Index Year: 2014 6.8 12.9 6.8 15.3 6.8 14.1 
Index Year: 2015 2.9 6.1 2.9 7.3 2.9 7.9 
Smoking a 7.7 13.4 7.7 11.3 7.7 13.5 
Diabetes-related Co-morbidities  
Nephropathy 8.4 15.3 8.4 3.7 8.4 2.2 
Neuropathy 19.5 29.9 19.5 14.8 19.5 4.1 
Retinopathy 19.3 26.1 19.3 12.2 19.3 1.8 
Diabetic Medication Use       
Thiazolidinediones 69.1 8.1 69.1 6.5 69.1 -- 
DPP-4i 11.3 11.5 11.3 6.7 11.3 -- 
Metformin 57.3 38.8 57.3 64.7 57.3 -- 
Sulfonylureas 51.0 37.9 51.0 32.4 51.0 -- 
Other b 6.8 7.2 6.8 3.6 6.8 -- 
SGLT-2i 0.2 0.2 0.2 0.1 0.2 -- 
Fast-Acting Insulin 6.9 31.2 6.9 6.4 6.9 -- 
Long-Acting Insulin 16.8 65.9 16.8 13.9 16.8 -- 
Other Co-morbidities   
Heart Failure  15.6 34.9 15.6 14.9 15.6 24.8 
COPD  14.1 23.8 14.1 15.1 14.1 23.1 
Myocardial Infarction 0.7 1.6 0.7 0.8 0.7 1.2 
Stroke 10.0 17.7 10.0 9.6 10.0 14.4 
History of Cancer 16.5 19.4 16.5 18.0 16.5 25.5 
Medication Use 
ACE 42.3 45.3 42.3 40.6 42.3 30.0 
ARB 18.5 18.9 18.5 15.2 18.5 14.5 
Beta Blockers 42.7 54.4 42.7 44.2 42.7 46.7 
Calcium Channel Blocker 29.1 34.9 29.1 28.9 29.1 31.9 
Loop Diuretics 23.7 42.2 23.7 20.6 23.7 25.0 
Statins 66.2 56.0 66.2 55.6 66.2 45.5 
a. Smoking was defined using a validated algorithm that has nearly perfect specificity and PPV, but poor 
sensitivity (27.9% [95% CI: 16.6-39.1%])111 
b. Other diabetic medications included alpha-glucosidase inhibitors, amylin analogs, glucagon-like peptide-1 
receptor agonists, & meglitinides. 
 
 44
Table 4.12. Distribution (%) of patient characteristics among the components of the non-pioglitazone 
referent group (New user) 
PIO* LA INSULIN PIO* MET PIO* Untreated 
N  5,752 18,700 5,752 99,830 5,752 422,397 
Demographics at Cohort Entry 
Age, mean (SD) 75.4 (6.9) 76.3 (7.8) 75.4 (6.9) 74.0 (6.3) 75.4 (6.9) 77.8 (8.0) 
Age, median (IQR) 74 (70,80) 75 (70,82) 74 (70,80) 72 (69,78) 74 (70,80) 77 (71,84) 
Male 45.0 43.7 45.0 42.3 45.0 36.5 
White 70.4 71.8 70.4 82.0 70.4 80.3 
Black 11.8 19.8 11.8 8.6 11.8 10.8 
Other (Asian, Hispanic, or 
Native American) 17.8 8.3 17.8 9.4 17.8 8.9 
Index Year: 2008 26.5 14.8 26.5 11.0 26.5 23.1 
Index Year: 2009 22.3 14.7 22.3 12.9 22.3 12.4 
Index Year: 2010 16.2 11.8 16.2 12.8 16.2 10.7 
Index Year: 2011 11.0 11.1 11.0 12.8 11.0 10.7 
Index Year: 2012 4.9 10.7 4.9 12.2 4.9 10.4 
Index Year: 2013 5.4 10.6 5.4 12.8 5.4 10.8 
Index Year: 2014 5.9 10.2 5.9 15.0 5.9 14.1 
Index Year: 2015 7.7 16.0 7.7 10.5 7.7 7.9 
Smoking a 9.2 18.4 9.2 12.6 9.2 13.5 
Diabetes-related Co-morbidities 
Nephropathy 5.8 11.1 5.8 1.4 5.8 2.2 
Neuropathy 10.1 18.0 10.1 5.5 10.1 4.1 
Retinopathy 8.0 12.6 8.0 3.3 8.0 1.8 
Diabetic Medication Use       
Thiazolidinediones -- -- -- -- -- -- 
DPP-4i -- -- -- -- -- -- 
Metformin -- -- -- -- -- -- 
Sulfonylureas -- -- -- -- -- -- 
Other b -- -- -- -- -- -- 
SGLT-2i -- -- -- -- -- -- 
Fast-Acting Insulin -- -- -- -- -- -- 
Long-Acting Insulin -- -- -- -- -- -- 
Other Co-morbidities   
Heart Failure  15.0 38.5 15.0 12.9 15.0 24.8 
COPD  16.9 30.0 16.9 16.0 16.9 23.1 
Myocardial Infarction 0.8 2.2 0.8 0.8 0.8 1.2 
Stroke 10.6 22.1 10.6 8.5 10.6 14.4 
History of Cancer 18.8 23.0 18.8 21.5 18.8 25.5 
Medication Use 
ACE 29.4 33.6 29.4 31.4 29.4 30.0 
ARB 15.0 12.5 15.0 13.0 15.0 14.5 
Beta Blockers 1.4 1.7 1.4 1.3 1.4 1.6 
Calcium Channel Blocker 28.9 32.8 28.9 28.8 28.9 31.9 
Loop Diuretics 19.7 39.4 19.7 17.9 19.7 25.0 
Statins 50.3 38.7 50.3 49.3 50.3 45.5 
a. Smoking was defined using a validated algorithm that has nearly perfect specificity and PPV, but poor 
sensitivity (27.9% [95% CI: 16.6-39.1%])111 
b. Other diabetic medications included alpha-glucosidase inhibitors, amylin analogs, glucagon-like peptide-1 




Table 4.13. Bladder cancer incidence among pioglitazone users compared to the non-pioglitazone referent group and some of its components 
(All-user: Overall Follow-up) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses  
PIO vs. non-PIO PIO  4.13(1.66-4.93)  129,539   960  221.6  1.14(1.06-1.22) 1.13(1.05-1.21) 1.10(1.01-1.20) 
 non-PIO 2.36(1.02-4.86)  1,247,157   6,372  194.9   
PIO vs. LA Insulin PIO  4.13(1.66-4.93)  129,539   960  221.6  1.14(1.04-1.24) 1.09(1.00-1.18) 1.17(1.04-1.33) 
 LA Insulin 2.23(0.99-4.44)  247,675   1,226  195.9   
PIO vs. MET PIO  4.13(1.66-4.93)  129,539   960  221.6  1.26(1.17-1.36) 1.22(1.13-1.32) 1.18(1.07-1.31) 
 MET 2.59(1.12-4.93)  454,912   2,206  176.1   
PIO vs. Untreated PIO  4.13(1.66-4.93)  129,539   960  221.6  1.12(1.04-1.22) 1.12(1.03-1.21) 1.18(1.00-1.40) 
 Untreated 2.30(0.95-4.48)  374,952   1,884  196.8   
Comparison Group As-Treated Analyses  
 1.58(0.99-3.03)  129,539   621  230.3  1.19(1.09-1.29) 1.18(1.09-1.28) 1.18(1.06-1.32) 
PIO vs. non-PIO PIO  1.75(0.90-3.71)  1,247,157   5,443  193.8   
 non-PIO 1.58(0.99-3.03)  129,539   621  230.3  1.17(1.06-1.29) 1.12(1.01-1.23) 1.28(1.10-1.49) 
PIO vs. LA Insulin PIO  1.85(0.99-3.75)  247,675   1,118  196.4   
 LA Insulin 1.58(0.99-3.03)  129,539   621  230.3  1.31(1.20-1.44) 1.28(1.17-1.40) 1.27(1.11-1.45) 
PIO vs. MET PIO  1.58(0.95-3.21)  454,912   1,686  175.6   
 MET 1.58(0.99-3.03)  129,539   621  230.3  1.18(1.07-1.29) 1.17(1.06-1.28) 1.31(1.06-1.63) 
PIO vs. Untreated PIO  2.30(0.95-4.48)  374,952   1,884  196.8   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end 
of enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-
supply plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-
treated analyses additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. 
All follow-up was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-
day induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each 
new user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts for 
age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), 
smoking, HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, 






Table 4.14. Bladder cancer incidence among pioglitazone users compared to the non-pioglitazone referent group and some of its components 
(New user: Overall Follow-up) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses  
PIO vs. non-PIO PIO  3.76(1.38-4.93)  5,468   38  221.5 1.13(0.82-1.55) 1.12(0.81-1.54) 1.16(0.83-1.63) 
 non-PIO 2.23(0.89-4.35)  602,642   2,947  195.9   
PIO vs. LA Insulin PIO  3.76(1.38-4.93)  5,468   38  221.5 1.56(1.02-2.39) 1.55(1.01-2.37) 1.66(1.02-2.71) 
 LA Insulin 1.56(0.44-3.38)  16,174   49  149.5  
PIO vs. MET PIO  3.76(1.38-4.93)  5,468   38  221.5 1.25(0.89-1.74) 1.21(0.87-1.68) 1.27(0.88-1.82) 
 MET 2.41(1.02-4.40)  95,616   444  178.9  
PIO vs. Untreated PIO  3.76(1.38-4.93)  5,468   38  221.5 1.12(0.81-1.55) 1.09(0.79-1.50) 1.17(0.83-1.65) 
 Untreated 2.30(0.95-4.48)  374,952   1,884  196.8  
Comparison Group As-Treated Analyses  
 1.24(0.83-2.22)  5,468   23  251.0  1.29(0.86-1.95) 1.29(0.85-1.94) 1.37(0.89-2.10) 
PIO vs. non-PIO PIO  1.79(0.82-3.88)  602,642   2,675  195.4   
 non-PIO 1.24(0.83-2.22)  5,468   23  251.0  1.49(0.89-2.48) 1.46(0.88-2.43) 1.64(0.89-2.99) 
PIO vs. LA Insulin PIO  1.22(0.44-2.33)  16,174   44  166.7   
 LA Insulin 1.24(0.83-2.22)  5,468   23  251.0  1.42(0.93-2.17) 1.39(0.91-2.12) 1.44(0.91-2.29) 
PIO vs. MET PIO  1.42(0.83-2.82)  95,616   320  174.5   
 MET 1.24(0.83-2.22)  5,468   23  251.0  1.30(0.86-1.96) 1.26(0.84-1.90) 1.38(0.89-2.13) 
PIO vs. Untreated PIO  2.30(0.95-4.48)  374,952   1,884  196.8   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end 
of enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-
supply plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-
treated analyses additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. 
All follow-up was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-
day induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each 
new user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts for 
age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), 
smoking, HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, 






Table 4.15. Bladder cancer incidence among pioglitazone users compared to the non-pioglitazone referent group and its components (All-use: 
Follow-up ≤2Y) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses  
PIO vs. non-PIO PIO  1.97(1.66-1.97)  129,539   489  225.4  1.18(1.08-1.30) 1.19(1.08-1.30) 1.16(1.03-1.31) 
 non-PIO 1.97(1.02-1.97)  1,247,157   3,538  190.7   
PIO vs. LA Insulin PIO  1.97(1.66-1.97)  129,539   489  225.4  1.16(1.03-1.30) 1.13(1.00-1.26) 1.20(1.02-1.42) 
 LA Insulin 1.97(0.99-1.97)  247,675   714  195.4   
PIO vs. MET PIO  1.97(1.66-1.97)  129,539   489  225.4  1.30(1.17-1.44) 1.26(1.14-1.40) 1.23(1.07-1.42) 
 MET 1.97(1.12-1.97)  454,912   1,214  174.1   
PIO vs. Untreated PIO  1.97(1.66-1.97)  129,539   489  225.4  1.21(1.08-1.34) 1.21(1.08-1.35) 1.34(1.05-1.70) 
 Untreated 1.97(0.95-1.97)  374,952   1,036  187.2   
 As-Treated Analyses  
PIO vs. non-PIO PIO  1.58(0.99-1.97)  129,539   425  227.8  1.19(1.07-1.31) 1.19(1.07-1.31) 1.18(1.04-1.35) 
 non-PIO 1.75(0.90-1.97)  1,247,157   3,355  191.3   
PIO vs. LA Insulin PIO  1.58(0.99-1.97)  129,539   425  227.8  1.16(1.02-1.30) 1.12(0.99-1.27) 1.23(1.03-1.46) 
 LA Insulin 1.85(0.99-1.97)  247,675   698  196.4   
PIO vs. MET PIO  1.58(0.99-1.97)  129,539   425  227.8  1.30(1.16-1.45) 1.26(1.13-1.41) 1.25(1.07-1.46) 
 MET 1.58(0.95-1.97)  454,912   1,117  175.5   
PIO vs. Untreated PIO  1.58(0.99-1.97)  129,539   425  227.8  1.21(1.08-1.36) 1.21(1.08-1.36) 1.35(1.04-1.76) 
 Untreated 1.97(0.95-1.97)  374,952   1,036  187.2   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end 
of enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within 
days-supply plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-
treated analyses additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. 
All follow-up was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-
day induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each 
new user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts 
for age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), 
smoking, HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, 





Table 4.16. Bladder cancer incidence among pioglitazone users compared to the non-pioglitazone referent group and its components (New 
user: Follow-up ≤2Y) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses  
PIO vs. non-PIO PIO  1.97(1.38-1.97)  5,468   21  239.5 1.27(0.82-1.95) 1.28(0.83-1.97) 1.41(0.91-2.20) 
 non-PIO 1.97(0.89-1.97)  602,642   1,659  189.3   
PIO vs. LA Insulin PIO  1.97(1.38-1.97)  5,468   21  239.5 1.46(0.85-2.51) 1.37(0.80-2.34) 1.64(0.85-3.15) 
 LA Insulin 1.56(0.44-1.97)  16,174   35  169.8  
PIO vs. MET PIO  1.97(1.38-1.97)  5,468   21  239.5 1.32(0.84-2.05) 1.29(0.83-2.01) 1.35(0.84-2.16) 
 MET 1.97(1.02-1.97)  95,616   262  182.5  
PIO vs. Untreated PIO  1.97(1.38-1.97)  5,468   21  239.5 1.28(0.83-1.97) 1.26(0.82-1.94) 1.43(0.92-2.24) 
 Untreated 1.97(0.95-1.97)  374,952   1,036  187.2  
 As-Treated Analyses  
PIO vs. non-PIO PIO  1.24(0.83-1.97)  5,468   18  257.6  1.35(0.85-2.15) 1.36(0.86-2.17) 1.49(0.92-2.41) 
 non-PIO 1.79(0.82-1.97)  602,642   1,588  189.7   
PIO vs. LA Insulin PIO  1.24(0.83-1.97)  5,468   18  257.6  1.40(0.79-2.48) 1.32(0.75-2.33) 1.61(0.80-3.21) 
 LA Insulin 1.22(0.44-1.97)  16,174   35  182.8   
PIO vs. MET PIO  1.24(0.83-1.97)  5,468   18  257.6  1.43(0.88-2.30) 1.39(0.86-2.25) 1.45(0.87-2.44) 
 MET 1.42(0.83-1.97)  95,616   229  179.6   
PIO vs. Untreated PIO  1.24(0.83-1.97)  5,468   18  257.6  1.38(0.86-2.19) 1.35(0.85-2.16) 1.53(0.94-2.48) 
 Untreated 1.97(0.95-1.97)  374,952   1,036  187.2   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end 
of enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-
supply plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-
treated analyses additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. 
All follow-up was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-
day induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each 
new user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts for 
age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), 
smoking, HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, 





Table 4.17. Bladder cancer incidence among pioglitazone users compared to the non-pioglitazone referent group and its components (All-
user: Follow-up >2Y) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses  
PIO vs. non-PIO PIO  2.96(1.77-2.96)  93,199   471  217.8  1.09(0.99-1.20) 1.07(0.97-1.18) 1.04(0.91-1.18) 
 non-PIO 2.46(1.09-2.96)  700,680   2,834  200.3   
PIO vs. LA Insulin PIO  2.96(1.77-2.96)  93,199   471  217.8  1.11(0.98-1.26) 1.04(0.92-1.18) 1.15(0.95-1.38) 
 LA Insulin 2.27(0.96-2.96)  134,269   512  196.6   
PIO vs. MET PIO  2.96(1.77-2.96)  93,199   471  217.8 1.22(1.09-1.36) 1.18(1.06-1.32) 1.13(0.98-1.32) 
 MET 2.61(1.14-2.96)  270,094   992  178.6   
PIO vs. Untreated PIO  2.96(1.77-2.96)  93,199   471  217.8  1.04(0.93-1.17) 1.03(0.92-1.15) 1.03(0.81-1.32) 
 Untreated 2.26(1.01-2.96)  206,483   848  210.0   
 As-Treated Analyses  
PIO vs. non-PIO PIO  1.44(0.56-2.63)  53,509   196  235.9  1.19(1.02-1.37) 1.16(1.00-1.35) 1.18(0.96-1.44) 
 non-PIO 1.97(0.79-2.96)  578,542   2,088  198.1   
PIO vs. LA Insulin PIO  1.44(0.56-2.63)  53,509   196  235.9  1.20(1.01-1.42) 1.11(0.93-1.32) 1.41(1.06-1.88) 
 LA Insulin 1.92(0.76-2.96)  118,656   420  196.5   
PIO vs. MET PIO  1.44(0.56-2.63)  53,509   196  235.9  1.34(1.14-1.58) 1.31(1.11-1.54) 1.31(1.02-1.69) 
 MET 1.62(0.62-2.96)  193,520   569  175.8   
PIO vs. Untreated PIO  1.44(0.56-2.63)  53,509   196  235.9  1.11(0.95-1.30) 1.09(0.93-1.28) 1.30(0.87-1.92) 
 Untreated 2.26(1.01-2.96)  206,483   848  210.0   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end 
of enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-
supply plus a 90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-treated 
analyses additionally added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. All follow-
up was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-day 
induction period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each new 
user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts for 
age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), 
smoking, CHF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, 






Table 4.18. Bladder cancer incidence among pioglitazone users compared to the non-pioglitazone referent group and its components (New 
user: Follow-up >2Y) 
Comparison Group Med(IQR) FUPa Nb Events Ratec Crude HRd Partial-adj HRd Fully-adj HRd 
 Initial-Treatment Analyses  
PIO vs. non-PIO PIO  2.93(1.67-2.96)  3,715   17  202.6 0.99(0.61-1.60) 0.96(0.60-1.56) 0.92(0.54-1.57) 
 non-PIO 2.19(0.98-2.96)  325,148   1,288  205.2   
PIO vs. LA Insulin PIO  2.93(1.67-2.96)  3,715   17  202.6 1.76(0.87-3.57) 1.92(0.94-3.94) 1.68(0.85-3.33) 
 LA Insulin 1.76(0.77-2.96)  7,003   14  115.1  
PIO vs. MET PIO  2.93(1.67-2.96)  3,715   17  202.6 1.17(0.71-1.92) 1.11(0.67-1.84) 1.17(0.67-2.06) 
 MET 2.13(0.99-2.96)  54,749   182  173.9  
PIO vs. Untreated PIO  2.93(1.67-2.96)  3,715   17  202.6 0.97(0.60-1.57) 0.93(0.57-1.50) 0.93(0.54-1.58) 
 Untreated 2.26(1.01-2.96)  206,483   848  210.0  
 As-Treated Analyses  
PIO vs. non-PIO PIO  1.15(0.47-2.29)  1,587   <11  229.9  1.11(0.46-2.68) 1.08(0.45-2.59) 1.03(0.39-2.75) 
 non-PIO 2.07(0.88-2.96)  284,196   1,087  204.4   
PIO vs. LA Insulin PIO  1.15(0.47-2.29)  1,587    <11   229.9  1.89(0.63-5.61) 2.10(0.71-6.21) 2.03(0.58-7.14) 
 LA Insulin 1.25(0.50-2.52)  4,960    <11   124.2   
PIO vs. MET PIO  1.15(0.47-2.29)  1,587    <11   229.9  1.41(0.57-3.48) 1.36(0.55-3.34) 1.33(0.46-3.80) 
 MET 1.43(0.58-2.73)  35,909   91  162.8   
PIO vs. Untreated PIO  1.15(0.47-2.29)  1,587    <11   229.9  1.08(0.45-2.59) 1.02(0.42-2.46) 1.00(0.38-2.68) 
 Untreated 2.26(1.01-2.96)  206,483   848  210.0   
a. Follow-up (years) started at cohort entry and was censored at first occurrence of outcome, death, end of study (December 2015), or end of 
enrollment. As-treated analyses additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-supply plus a 
90-day grace period).  A 180-day induction period was imposed excluding time from the beginning of follow-up. The as-treated analyses additionally 
added a 180-day latency period to the end of follow-up when possible prior to death or end of patient data. All follow-up was truncated at 5 years 
b. Number contributing who did not experience the outcome, death, end of study (December 2015), or end of enrollment during the 180-day induction 
period. Those who initiated PIO differs for each new user comparison due to exclusions of prior use of drugs included in each new user comparison. 
c. Incidence Rate reported per 100 000 Person-Years 
d. Cox proportional hazards models. Partially-adjusted model adjusted for age, age-squared, sex, and race; Fully-adjusted model adjusts for age, age-
squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), smoking, HF, MI, Stroke, 
prevalent cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop diuretics, statins, TZDs, DPP-4i’s, metformin, 
sulfonylureas, SGLT-2i’s, fast-acting insulin, long-acting insulin, other glucose-lowering drugs. 
 
 51
Table 4.19. Distribution (%) of urinary tract-related comorbidities among pioglitazone users & each 
referent  
 PIO Non-PIO PIO GLD PIO NIGLD PIO DPP 
All User, N 135,188   1,375,024  135,188 828,527  135,188 705,446  135,188 128,089  
Bladder Stone  0.2 0.3 0.2 0.3 0.2 0.3 0.2 0.3 
Kidney Stone 3.0 3.3 3.0 3.2 3.0 3.1 3.0 4.1 
TURBT 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 
Ureteral / renal 
pelvis cancer 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
UTIs 22.1 26.3 22.1 24.2 22.1 22.3 22.1 26.5 
New User, N 5,752 675,986 5,752 172,663 7,547 174,512 33,551 76,503 
Bladder Stone  0.2 0.3 0.2 0.3 0.2 0.3 0.3 0.3 
Kidney Stone 3.0 3.3 3.0 3.2 3.0 3.1 3.3 4.1 
TURBT <0.2 0.1 <0.2 0.1 <0.1 0.1 0.1 0.1 
Ureteral / renal 
pelvis cancer <0.2 0.1 <0.2 0.1 <0.1 0.1 0.1 0.1 
UTIs 21.9 27.9 21.9 24.1 25.6 23.7 24.5 28.4 
TURBT, Transurethral Resection of the Bladder tumor; UTI, Urinary Tract Infection 
 
Table 4.20. Distribution (%) of urinary tract-related comorbidities among pioglitazone users among 
the non-pioglitazone referent group and some of its components  
PIO Non-PIO PIO 
LA 
INSULIN PIO MET PIO 
Un-
treated 
All User, N 135,188  1,375,024 135,188  270,879  135,188  476,234  135,188 422,397  
Bladder Stone  0.2 0.3 0.2 0.3 0.2 0.3 0.2 0.3 
Kidney Stone 3.0 3.3 3.0 3.7 3.0 3.0 3.0 3.4 
TURBT 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 
Ureteral / renal 
pelvis cancer 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 
UTIs 22.1 26.3 22.1 33.2 22.1 20.8 22.1 30.2 
New User, N 5,752 675,986 5,752 18,700 5,752 99,830 40,084 422,397 
Bladder Stone  0.2 0.3 0.2 0.5 0.2 0.3 0.2 0.3 
Kidney Stone 3.0 3.3 3.0 3.8 3.0 2.9 3.0 3.4 
TURBT 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 
Ureteral / renal 
pelvis cancer 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
UTIs 21.9 27.9 21.9 37.6 21.9 19.2 21.9 30.2 












Figure 4.2. Study inclusion flowchart 
 
DPP, dipeptidyl-peptidase-4; GLD, Glucose-Lowering Drug; NIGLD, Non-Insulin Glucose-Lowering Drug; PIO, 
pioglitazone; RX, Prescription Claims  
 
a. PIO users that did not have ≥2 RX within 180 days were included in Referent #1, but excluded from Referent #2 
and #5.  
b. Number of PIO varies due to exclusion of prevalent users of the drugs of interest in each new user comparison  
  
REFERENT GROUPS EXPOSURE GROUPS 
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Figure 4.3. Fully-adjusted relative bladder cancer incidence rates among pioglitazone users & each 
referent  
 
Fully-adjusted hazard ratios obtained via multivariate Cox proportional hazards models that included age, age-
squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 
2010), smoking, HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, 
retinopathy, ACE, loop diuretics, statins, TZDs, DPP-4i’s, metformin, sulfonylureas, SGLT-2i’s, fast-acting insulin, 





All user: Initial-Treatment 1.10 (1.01-1.20)
All user: As-Treated 1.18 (1.06-1.32)
New user: Initial-Treatment 1.16 (0.82-1.64)
New user: As-Treated 1.37 (0.89-2.10)
PIO vs. GLD
All user: Initial-Treatment 1.08 (0.99-1.19)
All user: As-Treated 1.16 (1.04-1.30)
New user: Initial-Treatment 1.16 (0.82-1.65)
New user: As-Treated 1.34 (0.86-2.09)
PIO vs. NIGLD
All user: Initial-Treatment 1.10 (1.00-1.20)
All user: As-Treated 1.18 (1.05-1.32)
New user: Initial-Treatment 1.07 (0.77-1.47)
New user: As-Treated 1.22 (0.81-1.84)
PIO vs. DPP
All user: Initial-Treatment 1.13 (0.99-1.29)
All user: As-Treated 1.20 (1.01-1.42)
New user: Initial-Treatment 1.15 (0.95-1.40)
New user: As-Treated 1.31 (1.03-1.68)
FOLLOW-UP <=2YRS
PIO vs. Non-PIO
All user: Initial-Treatment 1.16 (1.03-1.31)
All user: As-Treated 1.18 (1.04-1.35)
New user: Initial-Treatment 1.41 (0.90-2.20)
New user: As-Treated 1.49 (0.92-2.41)
PIO vs. GLD
All user: Initial-Treatment 1.13 (1.00-1.28)
All user: As-Treated 1.14 (1.00-1.31)
New user: Initial-Treatment 1.30 (0.83-2.05)
New user: As-Treated 1.37 (0.83-2.23)
PIO vs. NIGLD
All user: Initial-Treatment 1.14 (1.00-1.29)
All user: As-Treated 1.15 (1.01-1.32)
New user: Initial-Treatment 1.20 (0.80-1.82)
New user: As-Treated 1.22 (0.77-1.93)
PIO vs. DPP
All user: Initial-Treatment 1.09 (0.91-1.31)
All user: As-Treated 1.14 (0.93-1.38)
New user: Initial-Treatment 1.17 (0.90-1.53)
New user: As-Treated 1.23 (0.92-1.64)
FOLLOW-UP >2YRS
PIO vs. Non-PIO
All user: Initial-Treatment 1.04 (0.91-1.18)
All user: As-Treated 1.18 (0.96-1.44)
New user: Initial-Treatment 0.92 (0.54-1.57)
New user: As-Treated 1.03 (0.39-2.75)
PIO vs. GLD
All user: Initial-Treatment 1.04 (0.91-1.18)
All user: As-Treated 1.19 (0.97-1.47)
New user: Initial-Treatment 1.00 (0.58-1.72)
New user: As-Treated 1.25 (0.46-3.39)
PIO vs. NIGLD
All user: Initial-Treatment 1.06 (0.93-1.21)
All user: As-Treated 1.22 (0.98-1.52)
New user: Initial-Treatment 0.91 (0.54-1.51)
New user: As-Treated 1.25 (0.50-3.09)
PIO vs. DPP
All user: Initial-Treatment 1.17 (0.95-1.43)
All user: As-Treated 1.38 (0.96-1.97)
New user: Initial-Treatment 1.13 (0.85-1.51)
New user: As-Treated 1.56 (0.97-2.52)
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Figure 4.4. Fully-adjusted relative bladder cancer incidence rates among pioglitazone users compared 
to the non-pioglitazone referent group and its components  
 
Fully-adjusted hazard ratios obtained via multivariate Cox proportional hazards models that included age, age-
squared, male sex, race (black, other, ref: white), cohort entry year (2008, 2009, 2011, 2012, 2013, 2014, 2015, ref: 
2010), smoking, HF, MI, Stroke, prevalent cancer based on all available data, nephropathy, neuropathy, 
retinopathy, ACE, loop diuretics, statins, TZDs, DPP-4i’s, metformin, sulfonylureas, SGLT-2i’s, fast-acting insulin, 





All user: Initial-Treatment 1.10 (1.01-1.20)
All user: As-Treated 1.18 (1.06-1.32)
New user: Initial-Treatment 1.16 (0.83-1.63)
New user: As-Treated 1.37 (0.89-2.10)
PIO vs. LA Insulin
All user: Initial-Treatment 1.17 (1.04-1.33)
All user: As-Treated 1.28 (1.10-1.49)
New user: Initial-Treatment 1.66 (1.02-2.71)
New user: As-Treated 1.64 (0.89-2.99)
PIO vs. Metformin
All user: Initial-Treatment 1.18 (1.07-1.31)
All user: As-Treated 1.27 (1.11-1.45)
New user: Initial-Treatment 1.27 (0.88-1.82)
New user: As-Treated 1.44 (0.91-2.29)
PIO vs. No GLD
All user: Initial-Treatment 1.18 (1.00-1.40)
All user: As-Treated 1.31 (1.06-1.63)
New user: Initial-Treatment 1.17 (0.83-1.65)
New user: As-Treated 1.38 (0.89-2.13)
FOLLOW-UP <=2YRS
PIO vs. Non-PIO
All user: Initial-Treatment 1.16 (1.03-1.31)
All user: As-Treated 1.18 (1.04-1.35)
New user: Initial-Treatment 1.41 (0.90-2.19)
New user: As-Treated 1.49 (0.92-2.41)
PIO vs. LA Insulin
All user: Initial-Treatment 1.20 (1.02-1.42)
All user: As-Treated 1.23 (1.03-1.46)
New user: Initial-Treatment 1.64 (0.85-3.15)
New user: As-Treated 1.61 (0.80-3.21)
PIO vs. Metformin
All user: Initial-Treatment 1.23 (1.07-1.42)
All user: As-Treated 1.25 (1.07-1.46)
New user: Initial-Treatment 1.35 (0.84-2.16)
New user: As-Treated 1.45 (0.87-2.44)
PIO vs. No GLD
All user: Initial-Treatment 1.34 (1.05-1.70)
All user: As-Treated 1.35 (1.04-1.76)
New user: Initial-Treatment 1.43 (0.92-2.24)
New user: As-Treated 1.53 (0.94-2.48)
FOLLOW-UP >2YRS
PIO vs. Non-PIO
All user: Initial-Treatment 1.04 (0.91-1.18)
All user: As-Treated 1.18 (0.96-1.44)
New user: Initial-Treatment 0.93 (0.54-1.57)
New user: As-Treated 1.03 (0.39-2.75)
PIO vs. LA Insulin
All user: Initial-Treatment 1.15 (0.95-1.38)
All user: As-Treated 1.41 (1.06-1.88)
New user: Initial-Treatment 1.68 (0.85-3.33)
New user: As-Treated 2.03 (0.58-7.14)
PIO vs. Metformin
All user: Initial-Treatment 1.13 (0.98-1.32)
All user: As-Treated 1.31 (1.02-1.69)
New user: Initial-Treatment 1.17 (0.67-2.06)
New user: As-Treated 1.33 (0.46-3.80)
PIO vs. No GLD
All user: Initial-Treatment 1.03 (0.81-1.32)
All user: As-Treated 1.30 (0.87-1.92)
New user: Initial-Treatment 0.93 (0.54-1.58)
New user: As-Treated 1.00 (0.38-2.68)
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Figure 4.5. Adapted funnel plot of published relative estimates against precision to demonstrate 
trends publication bias of existing literature 
 
Studies that censored follow-up based on exposure reported using “square” markers, while those that did not 
reported using “circle” markers. Studies that required new use reported using filled markers, while those that did 
not remain unfilled. For ease of presentation, the 3 data points with CLRs >10 (Song 2012, 65; Tolman 2009, 431; 
Nissen 2008, 806) are plotted with a CLR of 10.  
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CHAPTER 5. MANUSCRIPT 2: EVALUATE THE USE OF THE PROPOSED PREVALENT NEW USER DESIGN 
WITHIN MEDICARE CLAIMS 2007-2015 TO COMPARE ONE-YEAR HEART FAILURE HOSPITALIZATION 
RATE AMONG USERS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS (DPP-4I) TO USERS OF 
THIAZOLIHINEDIONES (TZD), ALLOWING FOR DPP-4I USERS TO SWITCH FROM TZD 
 
5.1. Introduction 
Thiazolidinediones (TZDs) are a second-line class of glucose-lowering drugs (GLDs) first approved 
in the US in 1999 that are known to increase the risk for heart failure (HF) and are contraindicated for 
patients with existing HF.2 TZDs were a very popular treatment for type 2 diabetes mellitus (T2DM) for 
many years, as highly effective in achieving and maintaining target glucose levels. 2 In 2006, a clinical 
alternative to TZD, dipeptidyl peptidase-4s inhibitors (DPP-4i) entered the US market, and its use 
increased while the use of TZD steadily declined after cardiovascular (CV) and bladder cancer safety 
warnings.77 Although one of the DPP-4i’s, saxagliptin, was found to increase HF hospitalizations when 
compared to placebo (HR, 1.27 [95% CI: 1.07-1.51]),112 an active comparator, new user design (ACNU) 
that compared DPP-4i’s to TZD reported a decreased risk of HF (RR, 0.71 [95% CI: 0.53-0.93].20 
The active comparator new user design (ACNU) with a referent that is a clinically meaningful 
treatment alternative has been recommended for comparative effectiveness research to reduce the 
potential for bias.73-75 The exclusion of prevalent users in the ACNU helps mitigate potential for selection 
bias. Confounding by severity can create selection bias if those prescribed the exposure and the referent 
are at different stages of disease progression, especially among those with chronic conditions like 
diabetes.73,74 A depletion of susceptibles can occur when those who tolerate a drug well remain on the 
drug while those most susceptible to the harm are selected out of the population at risk over time.73,113 
The ACNU has been criticized, however, because additionally excluding prevalent users might lead to 
smaller sample size if many new users of one of the drug classes compared have been 
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treated with the other drug class previously. Also, when studies do not restrict to new users of index 
treatment(s), estimates may adjust for variables along the causal pathway, which can bias estimation of 
treatment effects toward the null and under-estimate harm.82,84 The prevalent new user design (PNU) 
has been proposed to include all or most patients exposed to the newer drug, as it additionally allows 
for those who switch from the older drug to the newer drug to be included.21  
This paper aimed to evaluate the use of the proposed PNU and adaptations of the PNU to 
compare one-year HF hospitalization rates among Medicare beneficiaries using DPP-4i, a newer GLD, to 
users of TZD, an older GLD, allowing for DPP-4i users to switch from TZD.  
 
5.2. Methods 
5.2.1. Study Population and Exposure 
First, we created a base cohort of Medicare beneficiaries who initiated DPP-4i (largely sitagliptin 
and saxagliptin) or TZDs (largely pioglitazone) who initiated use between January 1, 2007 and September 
30, 2015 with no evidence of use of their own drug class within the 365 days prior (baseline period). 
Patients who received both drugs were considered for inclusion as both an exposed (DPP-4i) and a 
referent (TZD) initiator, keeping only the first continuous use period per patient per treatment, which 
ended at discontinuation allowing for a 90-day grace period or upon a prescription fill for the other drug. 
Next, we assessed each treatment group for evidence of use of the other drug during the baseline 
period.  DPP-4i initiators were classified as a “DPP-4i new user” if they had no evidence of TZD use 
during the baseline period, and a “DPP-4i switcher” if they had a continuous new use period of TZD use 
until DPP-4i initiation. We excluded 10% of DPP-4 initiators who had prior use of TZD during the baseline 
period, but not immediately preceding DPP-4i initiation. For all DPP-4i users, the index date was 
assigned based on the initial DPP-4i prescription fill.  TZD users were excluded if they had evidence of 
DPP-4i use during the baseline period.  
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To minimize the potential for selection bias, the following time-conditional exclusions were 
applied at the index date: less than 365 days of continuous enrollment prior, age less than 66 years, or 
any inpatient or outpatient HF or loop diuretic at any time prior using all available data. 
We then created 1:1 matched cohorts of DPP-4i and TZD users, based on the following steps:  
1. For each DPP-4i new user, an ACNU exposure set of potential matches was created that 
included all TZD new users.  
2. For each DPP-4i switcher, a switch-augment-continuer (SAC) exposure set of potential 
matches was created that included all TZD new users with a TZD prescription refill date that 
occurred on the day when TZD duration was equal to the prior TZD duration of the 
corresponding DPP-4i switcher (± 30 days), referred to here as “TZD continuers”.  
3. We combined all exposure sets and employed a multivariate conditional logistic regression 
model to estimate the propensity score (PS) of DPP-4i use based on time-conditional 
covariates on or within 365 days prior to the assigned index date with each exposure set as 
the strata. Due to the large size of the combined exposure set, we selected a random 
sample of 100 patients from each exposure set to estimate the conditional PS of initiating 
DPP-4i, with the resulting relative odds estimating the corresponding relative hazards.21 In 
addition to estimating 1 PS based on all combined exposure sets, we additionally estimated 
two separate PS, one for the combined ACNU and another for the combined SAC exposure 
sets.  
4. The PS of the exposed group was checked to confirm that it lied within the range of the PS 
of the unexposed members of the corresponding exposure set to verify the positivity 
assumption within each exposure set, else the exposure set was eliminated. 
5. For each DPP-4i new user, starting with the earliest index date and continuing in 
chronological order, a TZD new user with the closest PS to the corresponding DPP-4i new 
 
 60
user (from all members of the exposure set, not only the sampled ones) was selected from 
the ACNU exposure set to form a 1:1 matched pair. A max caliper of width equal to 0.2 of 
the standard deviation of the logit of the PS was set.114 Next, matches were attempted for 
each DPP-4i switcher from the SAC exposure sets. All matches were first done without 
replacement, as suggested for the PNU (each TZD user can only contribute one a match 
from single point in time across all exposure sets),21 and then with unlimited replacement 
(each TZD user can be matched as more than one observation with a different index claim 
date).   
This resulted in four types of 1:1 matched comparative cohorts each, using either 1 overall PS 
for combined exposure sets or two separate PS, one for ACNU exposure sets and another for SAC 
exposure sets, and matching with and without replacement.  
 
5.2.2. Outcome 
HF was defined as an inpatient diagnosis in any position of HF, rheumatic HF, malignant, benign, 
or unspecified hypertension with HF, hypertensive heart and kidney disease with HF that is malignant, 
benign, or unspecified and stage I-IV or V/end-stage (ICD-9: 428.x, 398.91, 402.01, 402.11, 402.91, 
404.01, 404.11, 404.91, 404.03, 404.13, 404.93). (Appendix 2) Hospitalization for HF using 428.x in the 
primary position was considered given near perfect specificity (>98%), but expanded upon due to very 
low sensitivity of 21% reported in a Medicare population.93 
 
5.2.3. Follow-up 
Follow-up began on the index date and continued until first occurrence of the outcome, 
disenrollment, study end (September 30, 2015), or a max follow-up of 365 days. The primary analyses, 
referred to here as the “as-treated” (AT) approach additionally censored follow-up upon discontinuation 
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of index treatment (no subsequent dispensing for initiated drug class within days-supply plus a 90-day 
grace period) or treatment cross-over. Additional analyses, referred to here as the “initial-treatment” 
(IT) approach follow the first treatment carried forward without censoring on treatment changes, similar 
to the intent-to-treat model used in RCTs.  
 
5.2.4. Covariates and Statistical Analysis 
Demographics were assessed at the time of the matched index date and prior medication use 
and comorbidities of interest, selected a priori, were assessed during the baseline period prior to 
matched index. All covariates were summarized via descriptive statistics and used to calculate the 
propensity to initiate DPP-4i. The crude incidence of 1-year HF (first event per patient) was calculated 
based on the Poisson distribution overall and for each treatment category. Crude Cox proportional 
hazards models with treatment as the only independent variable were used to estimate the hazard 
ratios (HRs) and 95% confidence intervals (CI) for incident outcome events. We also added a multivariate 
model stratified by year of index date to account for calendar-time trends. Differences in the 
confounder distributions were inspected for successful confounder balance of measured characteristics. 
Exposure-specific PS distributions were plotted to inspect the suitability of the matched referent 
groups.94 (See Figure S1) All data were analyzed in SAS, v9.4. The University of North Carolina at Chapel 
Hill institutional review board approved this study. 
 
5.3. Results 
A summary of patients who initiated DPP-4i that are included via each approach can be found in 
Table 5.1. Among the 61,987 DPP-4i users who met the inclusion criteria, 95% (N=59,058) were 
traditional new users without evidence of TZD during the baseline period (ACNU), and 5% (N=2,929) 
were switchers who had continuous TZD use until DPP-4i initiation (SAC).  From the 28,200 patients who 
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initiated TZD without prior DPP-4i use who met the included in the ACNU exposure sets, 19,916 patients 
were additionally included in SAC exposure sets. We were able to identify TZD matches for 48% of the 
DPP-4i new users and <1% of the DPP-4i switchers when matching was done without replacement, and 
we were able to identify matches for almost all DPP-4i patients (new users and switchers) when 
matching was done with unlimited replacement.  
Among all exposure sets after matching on duration, DPP-4i new users were similar in age to 
TZD new users, but less likely to be a race other than White or Black or use of a statin, and more likely to 
have a smoking-related claim, nephropathy, neuropathy, connective tissue disease or cancer, and use of 
an beta blocker, angiotensin receptor blocker (ARB), metformin, or long-acting insulin. (Table 5.2) DPP-4i 
switchers were similar in age to TZD continuers, but less likely or have a myocardial infarction (MI), and 
more likely to be a race other than White or Black, have a smoking-related claim, diabetic complications, 
chronic kidney disease, or urinary tract infections, and use of an ARB, sulfonylureas, or metformin. 
Patients who switched to DPP-4i from TZD were more likely than DPP-4i new users to be a race other 
than White or Black, and have more diabetic complications, and prior medication use, including 
sulfonylureas and metformin. TZD continuers had more diabetic complications, comorbidities, and prior 
medication use, including sulfonylureas and metformin than TZD new users.  
Time-conditional covariate distributions for all matching approaches can be found in Tables 5.3-
5.6. When 1:1 matching was done without replacement, covariate balance was achieved among the 
ACNU comparisons, but not among the small number included in the SAC matched comparisons. When 
1:1 matching was done with unlimited replacement using 1 overall PS, covariate balance was achieved 
among the ACNU comparisons, but there was imbalance among the SAC comparisons for race, smoking, 
prior medication use, and diabetic complications. This imbalance was attenuated when separate PS 
calculations were used for ACNU and SAC exposure sets, respectively. 
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When AT censoring was used for the primary method of matching without replacement, the 
one-year incidence of HF for DPP-4i new users compared to TZD new users was 23.4 vs. 28.6 per 1000 
person-years for the ACNU comparison (HR, 0.81 [95% CI: 0.72-0.91]). (Table 5.7) We were unable to 
identify enough matches to yield any HF events for the SAC comparison. When matching was done with 
unlimited replacement, the one-year incidence of HF was 25.0 vs. 32.0 per 1000 (HR, 0.74 [95% CI: 0.68-
0.80]) for new users of DPP-4i compared to new users of TZD, and 25.5 vs. 29.0 per 1000 for DPP-4i 
switchers compared to TZD continuers (HR, 0.87 [95% CI: 0.61-1.23]). When separate PS were used for 
ACNU and SAC exposure sets, the HR was attenuated to 0.77 [95% CI: 0.71-0.83] for the ACNU 
comparison, but there was an increased incidence of one-year HF for the SAC comparison (HR, 1.12 
[95% CI: 0.77-1.63]). When stratified by index year to account for calendar time trends, the HRs were 
attenuated for all comparisons except the SAC comparison that estimated 2 separate PS models and 
allowed for unlimited replacement, in which the magnitude of the HR increased (1.21 [0.82-1.78]). The 
HR estimates via IT censoring were similar but attenuated. (Table 5.8)  
 
5.4. Discussion and Conclusions 
This paper evaluated the use of the PNU and adaptations of the originally proposed design to 
compare one-year HF hospitalization rates among Medicare beneficiaries initiating DPP-4i to initiators of 
TZD, allowing for DPP-4i initiators to switch from prior TZD. When separate models were used to 
estimate the propensity to initiate DPP-4i and the propensity to switch to DPP-4i from TZD, DPP-4i new 
use compared to TZD new use was associated with a decreased risk for one-year HF (HR, 0.77 [95% CI: 
0.71-0.83]), which is similar to the relative risk of HF published previously from an unmatched ACNU 
that compared DPP-4i to TZD within 1 year (0.71 [95% CI: 0.53-0.93].20 However, switching from TZD to 
DPP-4i among prevalent TZD users was associated with an increased risk for HF compared to continuing 
TZD (HR, 1.12 [95% CI: 0.77-1.63]). The incidence rate of HF among DPP-4i new users and DPP-4i 
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switchers was similar, but the incidence rate among TZD continuers was less than TZD new users, which 
is likely due to a depletion of the TZD patients who were most susceptible to HF over time. The longer 
patients had previously been on TZDs, the less likely they are to develop HF, irrespective of whether 
they stay and TZD or switch to DPP-4i. In our example, the PNU estimate that combined both ACNU and 
SAC comparisons was similar to the ACNU majority that represented 95% of the patients. However, 
these results suggest potential for the SAC comparisons to bias safety estimates, potentially under-
estimating the true effect. Furthermore, it is difficult to interpret the PNU estimate that combines ACNU 
and SAC as it addresses two different causal questions, the relative difference of HF risk among DPP-4i 
new use versus TZD new use, and the relative difference of HF risk among those who switch to DPP-4i 
from TZD versus those who continue TZD.  
One of the suggested benefits of the PNU is that it allows for comparative drug studies to 
incorporate all or most patients exposed to the newer drug for a more comprehensive assessment of 
safety.21 In the example provided by Suissa et al., there are far more referent patients than exposure 
patients (79,683 sulfonylurea users vs. 6196 glucagon-like peptide-1 receptor agonist users), as is 
preferable for matching. Although this may be the case when newer drugs first enter the market, in our 
example, use of the older drug quickly declined as the newer drug gained favor. The PNU may therefore 
be limited when performing 1:1 matching without replacement, as the number exposed in the matched 
cohort is dictated by the number of unexposed available for matching. Medicare pharmacy claims (Part 
D) did not become available until 2006.90 Therefore, after the baseline enrolment requirement, we did 
not have data between 2001 and 2007 during the time when TZD was most frequently prescribed, which 
limited the referent matching pool. Although there were 61,987 DPP-4i users, there were only 28,200 
TZD users, so we were only able to identify matches for 46% when matching without replacement. In an 
attempt to identify matches for more DPP-4i users, we also matched with unlimited replacement, which 
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allowed us to identify matches for almost all DPP-4i users. When we matched with replacement, 89% of 
TZD patients were matched more than once and residual confounding was nearly eliminated.  
The implementation of the PNU proved to be challenging. Subjective decisions were required to 
deal with unique treatment patterns of a very small subset of patients. For example, some patients had 
multiple periods of TZD use prior to DPP-4i and it was therefore unclear how TZD duration should be 
calculated based on continuous use or cumulative use. This decision changes the initial exposure sets 
used for matching as based on duration of TZD use. In our example, we only considered the duration of 
the first eligible continuous use period. In contrast, with the ACNU, parameters (e.g. washout, allowable 
grace period, days supply) can be defined to define and include all eligible use periods between 
initiation and censoring (i.e. discontinuation, cross-over of treatment) consistently throughout the entire 
study period. Another added complexity is the computing power necessary to estimate the 1 overall PS 
for the exponentially large pool of combined exposure sets. For the ACNU, this included a copy of all TZD 
users for every single DPP-4i user. Although we followed the guidance provided by Suissa et al. to select 
a random sample of 100 patients from each exposure set to estimate the conditional PS of initiating 
DPP-4i21, it still took substantial computing power to generate the matched cohorts, as all covariates 
were required to be re-defined for every possible index date.  
Our example had other limitations encountered when implementing the PNU. First, in US claims, 
it is often difficult to accurately determine duration of prior use due to left truncation. In Medicare, we 
also do not know what medications a patient has taken prior to age 65 when they become Medicare 
eligible, which makes it difficult to determine treatment history and cumulative duration of use. Another 
potential limitation is that administrative claims do not include body mass index, lab values such as 
glycated hemoglobin (HbA1c) or cholesterol, or other lifestyle factors, such as diet and smoking status, 
which may be important predictors of HF. These factors may be important since the PNU relies heavily 
on time-conditional covariates to balance disease severity between switchers and continuers. 
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Furthermore, without access to the prescriber or medical records, it is difficult to determine why such 
patients switch. The indication for switching versus continuing therapy are likely important confounders 
that cannot be controlled for implementing the PNU in administrative claims.  
This implementation of the PNU design in the US Medicare population showed little advantage 
over the ACNU, as it was both complex and computationally challenging to add only 5% more DPP-4 
users. Furthermore, the lower incidence of HF among the TZD continuers suggests depletion of 
susceptibles and highlights some pitfalls in the causal interpretation of PNU results. In settings where 
the PNU may have advantages, estimating separate PSs for initiators and switchers may improve 




Table 5.1. Summary of Number of Exposed DPP-4i Patients Included in Each Comparative Cohort  
PS Matching Approach 
 
PS Estimation 
Used for Matching 




All DPP included via 
PNU (ACNU+SAC) 
Total number of DPP-4i users N/A 59,058 2,929 61,987 
Primarya     
No Replacementb  1 PS >28,181 (>48%) <11  (<1%) 28,192  (45%) 2 PS 28,181  (48%) 12  (<1%) 28,193  (45%) 
Unlimited Replacementc 1 PS 59,041  (>99%) 2,927  (>99%) 61,968  (>99%) 2 PS 59,044  (>99%) 2,927  (>99%) 61,971  (>99%) 
ACNU, Active Comparator New User Design; DPP-4i, Dipeptidyl peptidase-4 inhibitors; PNU, Prevalent New User 
Design; PS, Propensity Score; SAC, Switch-Augment-Continuer; TZD, Thiazolidinediones 
a. The primary analysis includes only TZD users who satisfy the 365-day baseline requirement to determine new 
use and calculate duration. 
b. Each TZD matched only 1 time 
c. Each TZD user can be matched an unlimited amount of times as more than one observation with a different 
index claim date  
d. The sensitivity analysis additionally includes patients who enter the database already on TZD without 
satisfying the365-day baseline requirement but have at least 1 year of continuous use. Since we cannot 
determine exact duration of use, these patients will be considered as potential matches to DPP-4i switchers who 





Table 5.2. Distribution of covariates (%) among the exposure sets used to estimate the propensity 
score for matching 










Demographics and Smoking Status at Index 
Age, mean (SD) 74.1 (6.45) 73.8 (6.24) 74.1 (6.29) 73.9 (6.29) 
Age 66 to <70 29.9 30.3 28.5 30.4 
Age 66 to <70 30.1 31.0 31.0 30.6 
Age 75 to <80 19.6 19.8 19.5 20.0 
Age 80 to <85 12.0 11.9 13.6 11.9 
Age 85+ 8.3 7.1 7.4 7.2 
Male 43.0 45.4 43.9 45.5 
White 76.0 72.7 69.8 71.5 
Black 10.1 10.7 10.5 11.2 
Other Race 13.9 16.6 19.7 17.3 
Smoking 9.9 7.4 8.6 7.1 
Medication Use Prior to Index 
Angiotensin-Converting Enzyme inhibitor  36.8 38.3 40.5 42.5 
Angiotensin Receptor Blockers 15.2 13.3 19.1 15.6 
Beta2 Antagonist 9.1 8.1 9.1 8.6 
Beta Blockers 37.9 33.6 37.1 35.1 
Calcium Channel Blockers 27.9 26.0 28.9 29.3 
Non-Loop Diuretics 16.6 17.4 18.1 19.1 
Statins 49.7 54.0 60.5 62.1 
Diabetic Medication Use Prior to Index 
Sulfonylureas 48.4 49.8 59.7 51.7 
Metformin 66.8 61.3 71.6 64.9 
Long-acting Insulin 9.9 8.1 9.8 8.8 
Diabetic Complications Prior to Index     
Nephropathy 6.7 5.5 8.5 6.5 
Neuropathy 17.2 14.8 19.6 15.9 
Retinopathy 14.3 14.5 18.9 15.7 
Comorbidities Prior to Index 
Chronic Kidney Disease 9.7 8.8 10.7 9.2 
Connective Tissue Disorder 28.4 25.7 27.8 26.1 
COPD 9.6 9.7 9.0 9.7 
Depression 12.7 11.1 13.8 12.4 
Gastrointestinal Disease 0.8 0.8 0.5 0.8 
Myocardial Infarction 0.4 0.4 <0.4 0.3 
History of Cancer 16.6 14.9 15.6 15.0 
Stroke 8.2 7.6 7.6 7.5 
Urinary Tract Infection 20.9 19.1 21.5 19.4 
ACNU, Active Comparator New User Design; DPP-4i, Dipeptidyl peptidase-4 inhibitors; PNU, Prevalent New User 
Design; PS, Propensity Score; TZD, Thiazolidinediones;  
a.The TZD observations used to estimate the propensity score included the 100 randomly selected TZD users 
from each exposure set from the 28,200 unique beneficiaries included in the ACNU exposure sets. Among which, 











N 28,187 28,187 
Demographics and Smoking Status at Index   
Age, mean (SD)  74.2 (6.3) 73.9 (6.2) 
Age 66 to <70 28.3 30.2 
Age 66 to <70 30.9 30.9 
Age 75 to <80 20.1 19.8 
Age 80 to <85 12.8 12.0 
Age 85+ 7.8 7.1 
Male 41.7 45.3 
White 74.9 72.7 
Black 9.1 10.7 
Other Race 15.9 16.6 
Smoking 7.2 8.2 
Medication Use Prior to Index   
Angiotensin-Converting Enzyme inhibitor 39.6 38.3 
Angiotensin Receptor Blockers 16.0 13.3 
Beta2 Antagonist 8.4 8.1 
Beta Blockers 37.4 33.6 
CCBs 27.9 26.1 
Non-Loop Diuretics 18.6 17.4 
Statins 64.2 54.0 
Diabetic Medications Prior to Index   
Sulfonylureas 54.0 49.8 
Metformin 69.0 61.4 
Long-acting Insulin 7.9 8.1 
Diabetic Complications Prior to Index   
Nephropathy 5.3 5.5 
Neuropathy 16.3 14.9 
Retinopathy 15.6 14.4 
Comorbidities Prior to Index   
Chronic Kidney Disease 9.3 8.8 
Connective Tissue Disorders 28.2 25.7 
COPD 10.3 9.7 
Depression 11.5 11.1 
Gastrointestinal Disease 0.8 0.8 
Myocardial Infarction 0.5 0.4 
History of Cancer 16.1 14.9 
Stroke 8.5 7.6 
Urinary Tract Infection 21.3 19.1 
DPP-4i, Dipeptidyl peptidase-4 inhibitors; PNU, Prevalent New User Design; 
PS, Propensity Score; SAC, Switch-Augment-Continuer; TZD, 
Thiazolidinediones 




Table 5.4. Distribution of covariates (%), separate PSs, matching without replacement 









N 28,181 28,181 12 12 
Demographics and Smoking Status at Index     
Age, mean (SD)  74.2 (6.3) 73.9 (6.2) 74.7 (9.2) 71.9 (5.4) 
Age 66 to <70 28.3 30.2 50.0 50.0 
Age 66 to <70 30.9 30.9 16.7 16.7 
Age 75 to <80 20.1 19.8 0 25.0 
Age 80 to <85 12.8 12.0 8.3 0 
Age 85+ 7.8 7.1 25.0 8.3 
Male 41.7 45.3 33.3 41.7 
White 74.9 72.7 75.0 25.0 
Black 9.1 10.7 8.3 25.0 
Other Race 16.0 16.6 16.7 50.0 
Smoking 7.2 8.2 8.3 8.3 
Medication Use Prior to Index     
Angiotensin-Converting Enzyme inhibitor 39.7 38.3 66.7 66.7 
Angiotensin Receptor Blockers 16.2 13.3 0 0 
Beta2 Antagonist 8.3 8.1 8.3 8.3 
Beta Blockers 37.2 33.6 25.0 25.0 
CCBs 27.8 26.1 25.0 33.3 
Non-Loop Diuretics 18.5 17.4 25.0 41.7 
Statins 64.1 54.0 66.7 91.7 
Diabetic Medications Prior to Index     
Sulfonylureas 53.8 49.8 25.0 41.7 
Metformin 68.9 61.4 75.0 66.7 
Long-acting Insulin 8.0 8.1 0 0 
Diabetic Complications Prior to Index     
Nephropathy 5.3 5.5 25.0 16.7 
Neuropathy 16.2 14.9 16.7 41.7 
Retinopathy 15.7 14.5 0 8.3 
Comorbidities Prior to Index     
Chronic Kidney Disease 9.4 8.8 25.0 41.7 
Connective Tissue Disorders 28.2 25.7 8.3 16.7 
COPD 10.3 9.7 0 8.3 
Depression 11.5 11.1 25.0 50.0 
Gastrointestinal Disease 0.8 0.8 8.3 0 
Myocardial Infarction 0.5 0.4 0 0 
History of Cancer 16.1 14.9 8.3 8.3 
Stroke 8.5 7.6 16.7 8.3 
Urinary Tract Infection 21.1 19.1 16.7 41.7 
DPP-4i, Dipeptidyl peptidase-4 inhibitors; PNU, Prevalent New User Design; PS, Propensity Score; 




Table 5.5. Distribution of covariates (%), single PS, matching with unlimited replacement 









N  59,041   59,041   2,927   2,927  
Demographics and Smoking Status at Index     
Age, mean (SD) 74.1 (6.4) 74.1 (6.5) 74.1 (6.3) 73.8 (6.1) 
Age 66 to <70 29.9 29.5 28.5 29.8 
Age 66 to <70 30.1 30.3 31.1 31.2 
Age 75 to <80 19.6 19.2 19.4 20.4 
Age 80 to <85 12.0 12.7 13.6 12.6 
Age 85+ 8.3 8.3 7.4 6.0 
Male 43.0 44.6 43.9 45.6 
White 76.0 75.3 69.9 65.2 
Black 10.1 10.2 10.5 12.2 
Other Race 13.9 14.4 19.7 22.6 
Smoking 11.4 11.1 9.2 5.2 
Medication Use Prior to Index     
Angiotensin-Converting Enzyme inhibitor 36.8 35.9 40.5 45.7 
Angiotensin Receptor Blockers 15.2 14.5 19.1 12.6 
Beta2 Antagonist 9.1 8.8 9.1 8.0 
Beta Blockers 37.9 36.8 37.1 31.1 
CCBs 27.9 27.8 28.9 27.1 
Non-Loop Diuretics 16.6 16.2 18.1 20.9 
Statins 49.7 48.3 60.4 68.6 
Diabetic Medications Prior to Index     
Sulfonylureas 48.4 46.9 59.7 55.5 
Metformin 66.8 60.0 71.6 56.3 
Long-acting Insulin 9.9 10.0 9.8 7.0 
Diabetic Complications Prior to Index     
Nephropathy 6.7 6.6 8.5 5.8 
Neuropathy 17.2 16.9 19.6 14.8 
Retinopathy 14.3 14.0 18.9 16.5 
Comorbidities Prior to Index     
Chronic Kidney Disease 9.7 10.0 10.7 8.5 
Connective Tissue Disorders 28.4 27.8 27.8 24.5 
COPD 9.6 9.5 9.1 10.3 
Depression 12.7 12.4 13.8 11.8 
Gastrointestinal Disease 0.8 0.8 0.5 1.0 
Myocardial Infarction 0.4 0.4 0.2 0.1 
History of Cancer 16.6 16.6 15.6 14.5 
Stroke 8.2 8.2 7.6 6.5 
Urinary Tract Infection 20.9 20.8 21.5 17.8 
DPP-4i, Dipeptidyl peptidase-4 inhibitors; PNU, Prevalent New User Design; PS, Propensity Score; 
SAC, Switch-Augment-Continuer; TZD, Thiazolidinediones 
Each TZD user can be matched an unlimited amount of times as more than one observation with a 




Table 5.6. Distribution of covariates (%), separate PSs, matching with unlimited replacement 









N 59,044 59,044  2,927   2,927  
Demographics and Smoking Status at Index     
Age, mean (SD) 74.1 (6.4) 74.2 (6.5) 74.1 (6.3) 73.8 (6.4) 
Age 66 to <70 29.9 29.5 28.5 31.2 
Age 66 to <70 30.1 30.3 31.1 30.5 
Age 75 to <80 19.6 19.5 19.4 20.3 
Age 80 to <85 12.0 12.3 13.6 10.5 
Age 85+ 8.3 8.5 7.4 7.5 
Male 43.0 44.6 43.9 47.8 
White 76.0 75.7 69.9 72.0 
Black 10.1 10.4 10.5 12.1 
Other Race 13.9 13.9 19.6 16.0 
Smoking 11.4 11.2 9.2 7.2 
Medication Use Prior to Index     
Angiotensin-Converting Enzyme inhibitor,  36.8 35.9 40.5 43.9 
Angiotensin Receptor Blockers 15.2 14.8 19.1 13.3 
Beta2 Antagonist 9.1 8.7 9.1 8.0 
Beta Blockers 37.9 36.9 37.1 34.7 
CCBs 27.9 27.8 28.9 29.4 
Non-Loop Diuretics 16.6 16.2 18.1 19.3 
Statins 49.7 48.6 60.5 62.4 
Diabetic Medications Prior to Index     
Sulfonylureas 48.4 47.2 59.7 45.8 
Metformin 66.8 60.0 71.6 59.3 
Long-acting Insulin 9.9 9.6 9.8 8.1 
Diabetic Complications Prior to Index     
Nephropathy 6.7 6.7 8.4 6.2 
Neuropathy 17.2 17.2 19.6 14.3 
Retinopathy 14.3 14.4 18.9 14.2 
Comorbidities Prior to Index     
Chronic Kidney Disease 9.7 9.7 10.7 8.8 
Connective Tissue Disorders 28.4 27.9 27.8 25.3 
COPD 9.6 9.2 9.1 10.7 
Depression 12.7 12.3 13.8 11.3 
Gastrointestinal Disease 0.8 0.8 0.5 1.2 
Myocardial Infarction 0.4 0.5 0.2 0.8 
History of Cancer 16.6 16.9 15.6 15.2 
Stroke 8.2 8.2 7.6 8.0 
Urinary Tract Infection 20.9 21.3 21.5 19.1 
DPP-4i, Dipeptidyl peptidase-4 inhibitors; PNU, Prevalent New User Design; PS, Propensity Score; 
SAC, Switch-Augment-Continuer; TZD, Thiazolidinediones 
a. Each TZD user can be matched an unlimited amount of times as more than one observation with a 





Table 5.7. 1-year heart failure incidence among DPP-4 vs. TZD users (As-Treated)  
Comparison 






PS Matched HR 
(95% CI)a 
PS Matched HR 
(95% CI) – 
Adjusted for 
Index Year 
Matching without Replacementb 
Matches Based on 1 overall Propensity Score for all exposure sets 
PNU DPP 28,192 (100%) 506 21,666 23.4 0.81(0.72-0.91) 0.94(0.83-1.08) 
  TZD 28,192 (100%) 561 19,653 28.5 1.00 (ref) 1.00 (ref) 
ACNU DPP NR (>99.9%) 506 21,662 23.4 0.81(0.72-0.91) 0.94(0.83-1.08) 
  TZD NR (>99.9%) 561 19,649 28.6 1.00 (ref) 1.00 (ref) 
SAC DPP <11 (<0.1%) 0 NR N/A N/A N/A 
  TZD <11 (<0.1%) 0 NR N/A N/A N/A 
Matches Based on 2 Propensity Scores: 1 PS for ACNU exposure sets; 1 PS for SAC exposure sets 
PNU DPP 28,192 (100%) 506 21,666 23.4 0.81(0.72-0.91) 0.94(0.83-1.08) 
  TZD 28,192 (100%) 561 19,653 28.5 1.00 (ref) 1.00 (ref) 
ACNU DPP NR (>99.9%) 506 21,662 23.4 0.81(0.72-0.91) 0.94(0.83-1.08) 
  TZD NR (>99.9%) 561 19,649 28.6 1.00 (ref) 1.00 (ref) 
SAC DPP <11 (<0.1%) 0 NR N/A N/A N/A 
  TZD <11 (<0.1%) 0 NR N/A N/A N/A 
Matching with Unlimited Replacementb 
Matches Based on 1 overall Propensity Score for all exposure sets 
PNU DPP 61,968(100%) 1078  43,073   25.0  0.74(0.69-0.81) 0.83(0.76-0.91) 
  TZD 61,968(100%) 1370  43,007   31.9  1.00 (ref) 1.00 (ref) 
ACNU DPP 59,041  (95.3%) 1021  40,833   25.0  0.74(0.68-0.80) 0.83(0.76-0.91) 
  TZD 59,041  (95.3%) 1300  40,606   32.0  1.00 (ref) 1.00 (ref) 
SAC DPP 2,927  (4.7%) 57  2,240   25.5  0.87(0.61-1.23) 0.91(0.63-1.31) 
  TZD 2,927  (4.7%) 70  2,401   29.2  1.00 (ref) 1.00 (ref) 
Matches Based on 2 Propensity Scores: 1 PS for ACNU exposure sets; 1 PS for SAC exposure sets 
PNU DPP 61,971 (100%) 1077  43,075   25.0  0.78(0.72-0.85) 0.87(0.80-0.96) 
  TZD 61,971 (100%) 1303  43,135   30.2  1.00 (ref) 1.00 (ref) 
ACNU DPP 59,044  (95.3%) 1020  40,836   25.0  0.77(0.71-0.83) 0.86(0.78-0.94) 
  TZD 59,044  (95.3%) 1250  40,769   30.7  1.00 (ref) 1.00 (ref) 
SAC DPP 2,927  (4.7%) 57  2,239   25.5  1.12(0.77-1.63) 1.21(0.82-1.78) 
  TZD 2,927  (4.7%) 53  2,366   22.4  1.00 (ref) 1.00 (ref) 
ACNU, Active Comparator New User Design; DPP, Dipeptidyl peptidase-4 inhibitors; NR, Not Reportable (due to 
cell<11); PNU, Prevalent New User Design; PS, Propensity Score; SAC, Switch-Augment-Continuer; TZD, 
Thiazolidinediones 
a. The PS model included the following covariates in the model: age at index date, age^4, a smoking-related 
claim, comorbidities (cancer, chronic kidney disease, connective tissue disorder, chronic obstructive pulmonary 
disease, depression, gastrointestinal disorder, stroke, urinary tract infection), diabetic complications 
(neuropathy, nephropathy, retinopathy), prior use of glucose-lowering drugs (glucagon-like peptide-1 receptor 
agonists, long-acting insulin, short-acting insulin, metformin, SGLT-2i, sulfonylureas), prior use of other 
medications (ACE, ARB, beta2 antagonists, bile acid sequestrants, carbonic anhydrase inhibitors, calcium channel 
blockers, statins, glycosides, niacin, non-loop diuretics, oral contraceptives, progestin, testosterone), and 
healthcare utilization metrics (number of days admitted and number of admissions, electrocardiogram 
procedures, office visits, skilled nursing facility admissions, PSA, blood tests, colonoscopies, emergency 
department visits, influenza vaccines, lipid panels, mammograms, and pap smears). 
b. When matching without replacement, each TZD user was matched only 1 time. When matching with unlimited 
replacement, each TZD user was matched an unlimited amount of times as more than one observation with a 
different index claim date. The highest number of re-matches was 60. 
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Table 5.8. 1-year heart failure incidence among DPP-4i vs. TZD users (Initial Treatment)  
 
Comparison 







PS Matched HR 
(95% CI)a 
PS Matched HR 
(95% CI) – 
Adjusted for 
Index Year 
Matching without Replacementb 
Matches Based on 1 overall Propensity Score for all exposure sets 
PNU DPP 28,192 (100%) 650  27,027   24.1  0.82(0.74-0.92) 0.93(0.83-1.04) 
  TZD 28,192 (100%) 738  25,628   28.8  1.00 (ref) 1.00 (ref) 
ACNU DPP NR (>99.9%) 626  27,035   23.2  0.82(0.74-0.92) 0.93(0.83-1.04) 
  TZD NR (>99.9%) 724  25,630   28.2  1.00 (ref) 1.00 (ref) 
SAC DPP <11 (<0.1%) 0  NR  N/A N/A N/A 
  TZD <11 (<0.1%) 0  NR  N/A N/A N/A 
Matches Based on 2 Propensity Scores: 1 PS for ACNU exposure sets; 1 PS for PNU exposure sets 
PNU DPP 28,193 (100%) 643  27,023   23.8  0.81(0.73-0.91) 0.92(0.82-1.03) 
  TZD 28,193 (100%) 738  25,630   28.8  1.00 (ref) 1.00 (ref) 
ACNU DPP 28,181  (>99.9%) 624  27,020   23.1  0.81(0.73-0.91) 0.92(0.82-1.03) 
  TZD 28,181  (>99.9%) 724  25,624   28.3  1.00 (ref) 1.00 (ref) 
SAC DPP 12  (<0.1%) 0  11  N/A N/A N/A 
  TZD 12  (<0.1%) 0  12  N/A N/A N/A 
Matching with Unlimited Replacementb 
Matches Based on 1 overall Propensity Score for all exposure sets 
PNU DPP 61,968(100%) 1352  53,209   25.4  0.77(0.72-0.83) 0.87(0.80-0.94) 
  TZD 61,968(100%) 1739  56,089   31.0  1.00 (ref) 1.00 (ref) 
ACNU DPP 59,041  (95.3%) 1252  50,568   24.8  0.76(0.71-0.82) 0.86(0.79-0.93) 
  TZD 59,041  (95.3%) 1209  53,483   22.6  1.00 (ref) 1.00 (ref) 
SAC DPP 2,927  (4.7%) 75  2,653   28.3  1.02(0.74-1.40) 1.07(0.77-1.49) 
  TZD 2,927  (4.7%) 77  2,793   27.6  1.00 (ref) 1.00 (ref) 
Matches Based on 2 Propensity Scores: 1 PS for ACNU exposure sets; 1 PS for PNU exposure sets 
PNU DPP 61,971 (100%) 1351  53,213   25.4  0.77(0.72-0.83) 0.87(0.81-0.95) 
  TZD 61,971 (100%) 1737  56,093   31.0  1.00 (ref) 1.00 (ref) 
ACNU DPP 59,044  (95.3%) 1252  50,571   24.8  0.76(0.71-0.82) 0.86(0.79-0.93) 
  TZD 59,044  (95.3%) 1301  53,483   24.3  1.00 (ref) 1.00 (ref) 
SAC DPP 2,927  (4.7%) 75  2,654   28.3  1.09(0.79-1.51) 1.15(0.82-1.61) 
  TZD 2,927  (4.7%) 71  2,760   25.7  1.00 (ref) 1.00 (ref) 
ACNU, Active Comparator New User Design; DPP, Dipeptidyl peptidase-4 inhibitors; NR, Not Reportable; PNU, Prevalent New 
User Design; PS, Propensity Score; SAC, Switch-Augment-Continuer; TZD, Thiazolidinediones 
a. The PS model included the following covariates in the model: age at index date, age^4, a smoking-related claim, 
comorbidities (cancer, chronic kidney disease, connective tissue disorder, chronic obstructive pulmonary disease, depression, 
gastrointestinal disorder, stroke, urinary tract infection), diabetic complications (neuropathy, nephropathy, retinopathy), 
prior use of glucose-lowering drugs (glucagon-like peptide-1 receptor agonists, long-acting insulin, short-acting insulin, 
metformin, SGLT-2i, sulfonylureas), prior use of other medications (ACE, ARB, beta2 antagonists, bile acid sequestrants, 
carbonic anhydrase inhibitors, calcium channel blockers, statins, glycosides, niacin, non-loop diuretics, oral contraceptives, 
progestin, testosterone), and healthcare utilization metrics (number of days admitted and number of admissions, 
electrocardiogram procedures, office visits, skilled nursing facility admissions, PSA, blood tests, colonoscopies, emergency 
department visits, influenza vaccines, lipid panels, mammograms, and pap smears). 
b. When matching without replacement, each TZD user was matched only 1 time. When matching with unlimited 
replacement, each TZD user was matched an unlimited amount of times as more than one observation with a different index 
claim date. The highest number of re-matches was 60. 
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CHAPTER 6. CONCLUSIONS AND PUBLIC HEALTH SIGNIFICANCE 
6.1. Summary of Key Findings 
Using the example of pioglitazone and bladder cancer among older adults, Aim 1 results 
highlight how effect estimates can change due to variation of study design choices. When treatment 
changes were ignored and all users were included, estimates were generally closer to null, suggesting no 
increased risk. The HRs increased to 1.20 [95% CI: 1.01-1.42] when we restricted to new users, censored 
follow-up to accounted for treatment change, and used a clinically meaningful treatment alternative, 
DPP-4i, as the referent. There were also important differences identified within the composite referent 
group of all nonusers of pioglitazone, indicating that long-acting insulin users were at more severe stage 
of diabetes than pioglitazone users, metformin users, and the untreated, respectively. The results 
suggest that most of the wide variation of effect estimates previously reported are a result of 
heterogeneity of study design choices.  
Using the example of one-year HF hospitalization rates among users of DPP-4 compared to users 
of TZD, allowing for DPP-4i users to switch from TZD, Aim 2 evaluated the use of the proposed PNU. 
When separate models were used to estimate the propensity to initiate DPP-4i and the propensity to 
switch to DPP-4i from TZD, DPP-4i new use compared to TZD new use was associated with a decreased 
risk for one-year HF (HR, 0.77 [95% CI: 0.71-0.83]), which is similar to the relative risk of HF published 
previously from an unmatched ACNU that compared DPP-4i to TZD within 1 year (0.71 [95% CI: 0.53-
0.93].20 However, switching from TZD to DPP-4i was associated with an increased risk for HF compared 
to continuing TZD (HR, 1.12 [95% CI: 0.77-1.63]). The incidence rate of HF among DPP-4i new users and 
switchers was similar, but the incidence rate among TZD continuers was less than TZD new users, which 
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is likely due to a depletion of the TZD patients who were most susceptible to HF over time. Despite 
previous suggestions that the PNU allows for comparative drug studies to incorporate all or most 
patients exposed to the newer drug for a more comprehensive assessment of safety,21 our 
implementation of the PNU in the US Medicare population showed little advantage, as was both 
complex and computationally challenging to add 5% more DPP-4i users. Furthermore, the lower 
incidence of HF among the TZD continuers suggests depletion of susceptibles and highlights some 
pitfalls in the causal interpretation of PNU results. 
 
6.2. Significance and Future Directions 
 When drugs enter the market, we know very little about their safety based on randomized trial 
data. Among other limitations, trials often have poor generalizability given that many patients, such as 
older adults and those with multiple comorbidities, are under-represented. Diabetes affects at least one 
in five older adults (age ≥65) in the US and over 86% of older adults with diabetes require treatment 
with one or more glucose-lowering drug (GLD).14 The continued demand for new GLDs compels the need 
for robust observational methods to improve the value of real-world evidence (RWE) from observation 
research evaluating the safety of diabetic medications. Although there is no one-size-fits-all approach 
and recommendations may depend on the data source and the research question, this dissertation 
highlights the importance of educating researchers and clinicians to understand the implications of 
methodological study design choices on interpretation of estimates, including but not limited to how 
exposure is defined, what exposure is compared to, and when safety endpoints are ascertained. Better 
methods will minimize the bias of future observational studies, which will ultimately lead to safer drugs 





APPENDIX 1. EXPOSURE DEFINITIONS 
 




Amylin analog pramlintide 
Biguanides Metformin, metformin/amino acid, pioglitazone/ metformin, saxagliptin/ 
metformin, sitigliptin/ metformin, alogliptin/ metformin, linagliptin/ metformin, 





saxagliptin, sitigliptin, linagliptin, alogliptin, sitigliptin/ simvastatin, saxagliptin/ 






Long-acting Insulin Apidra, Humalog, Humulin BR/N/R, Iletin I NPH/Protamine/Regular, Insulatard, 
Novolin N/R, Novolog, Velosulin 
Meglitinides repaglinide, nataglinide, repaglinide/ metformin 
Short-acting Insulin Humulin L/U, Iletin I Lente/ Semilente/Ultralente, Lantus, Lentard Insulin, 





Sulfonylureas acetohexamide, chlorpropamide, tolazamide, tolbutamide, glyburide, 
glimepiride, glipizide, glyburide/ metformin, glipizide/ metformin, pioglitazone/ 
glimepiride, rosiglitazone/ glimepiride 
Thiazolidinediones 
(TZD) 
pioglitazone, pioglitazone/ alogliptin, pioglitazone/ metformin, pioglitazone/ 
glimepiride 
 










Codes  Description  
Incident Bladder Cancer 
ICD-9: 188.x; ICD-10: C67.x Malignant neoplasm of bladder 
ICD-9: 233.7; ICD-10: D09.0 Carcinoma in situ of the bladder 
ICD-10: C79.11 Secondary malignant neoplasm of bladder 
  
Prevalent Bladder Cancer (Added For Exclusion Criteria) 
ICD-9: V10.5, V10.50, V10.51 Diagnosis of personal history of bladder cancer 
CPT-4: 90586 Bacillus Calmette-Guérin immunotherapy (BCG) 
CPT-4: 51720 Bladder instillation of a chemotherapeutic agent 
CPT-4: 51570, 51575, 51580, 51585, 
51590, 51595, 51596, 51597 
Cystectomy 
ICD-9: 00.10 Implementation of chemotherapeutic agent 
ICD-9: 96.49 Other genitourinary instillation 
ICD-9: 99.25 Injection or infusion of cancer chemotherapeutic substance 
  
Incident Heart Failure 
ICD-9: 428.x Heart Failure 
ICD-9: 398.91 Rheumatic HF 
ICD-9: 402.x1 Hypertension with HF (malignant, benign, or unspecified) 
ICD-9: 404.x1/404.x3 Hypertensive heart and chronic kidney disease with HF 
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